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INTRODUCTION 
 
“HEALTH IS A STATE OF COMPLETE PHYSICAL, MENTAL, AND SOCIAL 
WELL BEING AND NOT MERELY THE ABSENCE Of DISEASE OR INFIRMITY” 
-Defined By Worldhealth Organisation 
               The siddha system of medicine is comprises of the physical, psychological and 
social health. It serves to the humanity for more than thousands of years in defeating 
diseases. The system is based upon certain never failing “LAWS OF NATURE” and 
human life, revealed and realised by the learned yogis who were called siddhars. Siddhars 
were of the concept of healthy soul can only be developed through a healthy body. So 
they developed methods and medication that are believed to strengthen their physical 
body and there by their souls.  
                         “THE GLORY OF GOD IS TO CONCEAL A THING,  
     THE GLORY OF THE KING IS TO SEARCH IT OUT” 
                    The siddha system is based on mei gnana thathuvam.  In this system siddhars 
used thrithoda- panjapootham relativity theory for diagnosing and used panjapootha- 
arusuvai theory for treating the disease 
               “ÁÚôÀÐ ¯¼ø §¿¡ö ÁÕó¦¾ÉÄ¡Ìõ 
                ÁÚôÀÐ ¯Ç§¿¡ö ÁÕó¦¾Éî º¡Öõ 
                ÁÚôÀÐ þÉ¢§¿¡ö ÅÃ¡¾¢ÕôÀ 
                ÁÚôÀÐ º¡¨Å ÁÕó¦¾ÉÄ¡§Á.” 
                                                                                   -   ¾¢ÕãÄ÷ 
                        Now a days, urbanization and industrialization cause more allergic 
disorders. Allergies are common group of disorders seen worldwide and their incidence 
at an alarming accelerating rate. 
                        SWASA KASAM (bronchial asthma) is one among the allergic diseases. 
It’s becoming a major health issues in many developing countries. Many factors have 
contributed to the rise of the problem of BRONCHIAL ASTHMA. Increasing air 
pollution, fast modernization and widespread construction work are some of the reason 
for the asthma thrives. Diet becoming more westernized, improvement in standard of 
living, decreased in exercise rates, more dust mites and more population have been 
blamed. 
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                       In India 5.1 estimated deaths per 100000 population which is revealed by 
WHO (2004). It constitutes 0.2% of all deaths and 0.5% of National Burden of Disease. 
                           So I hope this is the right time to give a most excellent medicine for 
treating this serious illness with the herbo mineral preparation LINGA MAATHIRAI 
which is used for several years. 
                      Apart from internal medication, yogic practice like pranayamas, and some 
other breathing exercises are most viable points of treatment. This is the only measure for 
preventing SWASA KASAM. 
 
                                           "À¢Ã¡½ý ÁÉò¦¾¡Îõ §ÀÃ¡ ¾¼ì¸¢ô 
                                    À¢Ã¡½ý þÕì¸¢ø À¢ÈôÀ¢Èô À¢ø¨Ä 
                                    ÅÇ¢Â¢¨É Å¡í¸¢ ÅÂò¾¢ø «¼ì¸¢ø 
                                    ÀÇ¢í ¦¸¡òÐì ¸¡Âõ ÀÆì¸¢Ûõ À¢ïº¡õ" 
                                                                          
                                                                                                                                                                         
                                                                                          -¾¢ÕÁó¾¢Ãõ 
                         - 
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AIM AND OBJECTIVE 
AIM: 
         The aim of the dissertation Study is to analyze the disease Swasa kasam, both 
clinically and experimentally with the trial drug of Linga Mathirai. 
OBJECTIVE: 
1. To collect the literature of both siddha and modern aspects of the disease Swasa 
kasam . 
2. To study the clinical course of the disease with observation on the etiology, 
classification, pathology, differential diagnosis, prognosis, complications and 
treatment by siddha aspect. 
3. To have an idea about the incidence of the disease with age, occupation,     
economical status, habits, family history and climate conditions. 
4. To expose the clinical diagnostic methods mentioned by Siddhars to know how the 
disease manifest due to the deranged mukkutram, pori pulangal, ezhu udal 
thathukkal. 
5. To have detailed clinical investigations. 
6. To have a clinical trial on the disease Swasa kasam with the siddha drug Linga 
Mathirai. 
7. To evaluate the 
 Chemical, (Qualitative and Quantitative) 
 Toxicological (Acute and Sub-acute) 
 Pharmacological (Bronchodilator and Antihistamine activity in Guinea  
pig) 
 Bio-Statistical analysis 
To have the modern parameters to confirm the diagnosis and prognosis of the disease.          
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REVIEW OF LITERATURE  
SIDDHA ASPECT 
 
 Siddha system of medicine embraces physical, mental and spiritual aspects of the 
patients. The diseases are classified into 4448 types in out ancient siddha litertures based 
on Vatha, Pitha and Kabha theory. 
 
   ‘ehslh ehw;gj;J ehY E}W 
   eaKlNd ehw;gj;J vl;L Nuhfk;” 
- mfj;jpah; ,uj;jpdr; RUf;fk; ehb 
(Neha; ehly; jpul;L - 1 - 335) 
 
 Yugi munivar describes Swasa kasam as one of the categorized classification of 
Erumal Noi. They have explained in detail, the ethiology, Pathology, Clinical Features, 
Diagnosis based upon Mukkutrams, Eight Diagnostic Methods of Siddha, Prognosis, 
Treatment and Preventive methods. 
 
ERUMAL NOI: 
Synonyms of Erumal Noi 
 Kasam 
 Eelai 
 
Definition 
 According to siddha medicine erumal is a sound produced generally by smoke or 
dust entering the mouth and the nostrils. It is a sound produced while expelling the 
sputum. 
Aetiology 
 According to Yugi Muni, 
   ‘ghzj;jhy; gukhf;fpdp kpFf;ifahYk; 
    ghukh khkprq;fs; Grpf;ifahYk; 
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   jhzj;jhw; rQ;rhue; jtph;ifahYk; 
    rhpg;glhg; gjhh;j;jq;fs; Grpj;jyhYk; 
   jPzj;jhw; nghrpah kypUf;if ahYk; 
    Nrapioahh; Nkypd;gQ; rpijtjhYk; 
   khzj;jhy; khJf;f kiljyhYk; 
    kjj;jhYQ; RthrkJ kUTq; fhNz” 
   ‘Ntfpd;w tjpfkhk; GifapdhYk; 
    kPWfpd;w ghzj;jhy; kpf;Fe;jhNd”. 
        -  A+fpitj;jpa rpe;jhkzp 800 (269) 
 Excessive smoking 
 More intake of cool drinks 
 Starvation 
 Excessive non vegetarian diet 
 Improper diet 
 Exposure to cold and chill air 
 Excessive intake of kabha diet like ice cream, cool drinks etc. 
 Inhalation of smoke, various fumes, pollen grains and dust particles 
 Inhalation of irritating and obnoxious substances 
 Any obstruction in the respiratory tract 
 When food particles enter into the air passage. 
 
Pararasa Segaram describes the Erumal Noi as, 
 
  ‘Gifkpff; Fbj;jyhYk; Giunawpe;jhYk; Ngha; te; 
   jpfyNt elf;if ahY kpak;GKl; lzj;jpdhYk; 
  jifgrpj; jpUf;if ahYQ; rykyq; fopah jhYk; 
   mfKwg; gpuhz thA tfd;WNk Ndhf;Fe; jhNd 
  MdNjh iuAk; gpj;J kijtpisj; jpUkpj; js;spf; 
   fhdkhq; Foyha; fk;kpf; fdj;JW kplWq; fhJk; 
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  jhdJ jpdth ad;de; jd;idA kwg;gpj; Njjhd; 
   Cdkhq; fhr Neha;te; JWnkd ciuj;jpBNu”. 
        -   ghuhrNrfuk;> ehd;fhtJ ghfk; (193)  
It is described as, 
 Excessive smoking 
 Excessive walking 
 Excessive heat 
 Starvation 
 Improper excretion of urine and feces 
 
In Dhanvanthiri Vairhiyam, Erumal Noi is described as, 
 
 ‘mf;fpdp ke;je; njhz;il ahpFu ydk;nt Wj;jy; 
 ff;fpa tpUky; njhz;il fhe;Jjy; jpdTz;lhjy; 
 njhf;fpdpw; RuKz;lhjy; R+Ls gjhh;j;je;Njl 
 ypf;Fz fhrNuhf Tw;gt nkd;dyhNk” 
       -   jd;te;jphp itj;jpak; (157) 
 Loss of appetite 
 Throat irritation 
 Throat pain 
 Avoidance of food 
 Cough 
 Pyrexia 
 Desire to eat hot food substances 
 
In Theraiyar Vagadam, Erumal Noi is described as, 
 ‘te;jpLk; nts;Nshf;fhsk; thaJ jpj;jpg;ghFk; 
  nehe;jpLk; gplup kz;il ke;jKk; kpisg;gp Ndhq;Fk; 
 Ke;jNt jiyjh ndhe;J rhPuK KfKq; Fj;Jk; 
  fe;juj; njhz;il ehrp fu fud;WlNd Jk;ky; 
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 Jk;kY kpUkYe; Njhd;Wq; fhrNeha; 
  ed;ikaha; tpahjp jPh;e;njhopa ey;Fthh; 
 nrk;ikah apd;guq; fpupaw; nry;tdhh; 
  ck;ikah nahUngUk; Nahf NkhJthNu” 
       -   Njiuah; tiflk; (66) 
It is described as, 
 Belching 
 Sweet taste 
 Loss of appetite 
 Head ache 
 Pain all over the body especially in neck and face 
 Soreness of throat 
 Irritation in the nose and throat 
 Cough 
 
Erumal Noi is described in Aavi Allikkum Amutha Murai Surukkam as, 
 Burning sensation in the throat 
 Cough with expectoration 
 Haemoptysis 
 Throat pain 
 Vomiting 
 Tiredness 
 Nasal irritation 
 Loss of weight 
 Pain all over the body 
 Head ache 
 Flatulence 
-  Aavi Allikkum Amutha Murai Surukkam (384) 
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 According to YugiMuni, Erumal Noi or Kasam is divided into 12 types. 
 
‘jhdhd fhrkJ gd;dpuz;lhFe; 
 jhf;fhd ke;jhu fhre;NjhL 
ghdhd gf;f ke;jhu fhrk; 
 ghq;fhd Rlh;fhrk; thjfhrk; 
Ngdhd gpj;jkhq; fhrj;NjhL 
 Ngh;nghpa Rthrfhrj; Njhnlhf;f 
Vdhd ,uj;jkhq; fhrj;NjhL 
 ,iug;ghd rpNyj;k fhrj;jhdhNk 
Mfpd;w gPdprj;jpd; Rthrfhrk; 
 mopthj gpj;jj;jpd; fhrkhFk; 
Nghfpd;w gpj;jrpNyj;Jk fhre;jhNd 
 Gfo;nghpa njhe;jkhq; fhrj;NjhL 
Njfpd;w fhrkJ gdpuz;lhFk; 
 njspthf gpjDila nraiyf; Nfsha; 
Ntfpd;w tjpfkhk; GifapdhYk; 
 kPWfpd;w ghzj;jhy; kpFf;Fe;jhNd” 
- a+fpitj;jpa rpe;jhkzp 800 (269) 
 
1. Manthara Erumal 
2. Pakka Manthara Erumal 
3. Chudar Erumal 
4. Vali Erumal 
5. Azhal Erumal 
6. Swasa Erumal 
7. Raththa Erumal 
8. Iya Erumal 
9. Peenisa Erumal 
10. Vali Azhal Erumal 
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11. Azhal Iya Erumal 
12. Mukkutra Erumal 
 
 
Apart from these other types of irumal are , 
• Maruntheedu Erumal 
• Kanja Erumal 
• Kall Erumal 
• Sura Erumal 
• Kuruthi vaanthi Erumal 
Swasa kasamis one among the 12 classified categories of Erumal Noi. The major 
symptoms are Cough with Expectoration, Dyspnoea, Throat Irritation and Nasal 
Irritaiton. 
 
Yugi Muni describes Swasa kasamas, 
 
‘tz;ikaha;f; Nfhiofl;b ,Ukp tpOk; 
 khehfk; NghyNt thq;FQ; Rthrk; 
jpz;ikaha;r; nrUkYz;lh kbf;f bf;Fr; 
 rPuzkpyhkNy tapW %Jk; 
ed;ikaha; ehrpaJ jzy;Ngh yhFk; 
 eype;Jlk;G tw;wptUq; FuYq; fk;Kk; 
cz;ikah Az;zhf;fp Y}Wq; Nfzp 
 Aoe;JNk Rthrfh rj;jpndhg;Ng”. 
    -   A+fp itj;jpa rpe;jhkzp 800 (272) 
 
 Cough with expectoration 
 Dyspnoea 
 Throat irritation 
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 Indigestion 
 Flatulence 
 Nasal Irritation 
 Loss of weight 
 Change in Voice 
 Excessive salivation 
 
According to Siddhar Handwritten Script, Swasa kasamis described as, 
‘fl;bNa Nfhio ,UkNt tPo;e;J 
 fr;nrtp rPWjy; Nghy 
Kl;bNa %r;R td;ikaha;r; nrUkp 
 %f;foy; va;jpNa Alyk; 
tw;wpNa nkype;Jz;zhtiu ePUk; 
 tul;rP uzkpF tpah;it> 
fl;b Nghy; tapW %jpbypiug;gh 
 kpUknyd;NwhJth; fhNz” 
    -   Neha; ehly; jpul;L 11 (114) 
It is described as, 
 Cough with Expectoration 
 Dyspnoea 
 Loss of weight 
 Loss of appetite 
 Sweating 
 Flatulence 
 
According to Aavi Allikum Amutha Murai Surukkam, the signs of Swasa kasamare 
described as, 
 Cough 
 Fever with rigor 
 Dyspnoea 
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 Head ache 
 Flatualence 
 Vomiting 
 Constipation 
 Sweating 
 Excessive thirst 
-  Aavi Allikum Amutha Murai Surukkam  (389) 
In Rajavaidhya Pothini Erumal Noi is described as, 
 Flatulence 
 Indigestion 
 Cough with expectoration 
 Dryness of nasal region 
 Hoarseness of voice 
 Neuritis along the spinal region 
 Dyspnoea 
 Restlessness 
 Lassitude 
-  Rajavaidhya Pothini (24) 
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DIFFERENTIAL DIAGNOSIS (NOI NITHANAM) 
Manthara Erumal 
 Rhinitis 
 Sneezing 
 Tightness of chest 
 Dyspnoea 
 Sweating in the face, ear and all over the body 
 Cough with expectoration 
  
Pakka Manthara Erumal 
 Cough 
 Tightness of chest 
 Flatulence 
 Rhinitis 
 Dyspnoea 
 Hoarseness of Voice 
 All the symptoms varies with full and new moon days 
 
Iya Erumal 
 Dyspnoea 
 Cough with expectoration 
 Abdominal distension 
 Weight loss 
 Fever 
 Vomiting 
 Pain all over the body 
24 
   
 
 
Iya Eraippu Noi 
 Dyspnoea 
 Couth with expectoration 
 Rhinitis 
 Sweating 
 Chest pain 
 Fever and shivering all over the body 
 All these symptoms ends in fatal condition 
 
Eraippu Iya Noi 
 Dyspnoea 
 Cough with expectoration 
 Tightness of chest 
 Fever 
 Giddiness 
 Dryness of mouth 
 Rhinitis 
 
MUKKUTRA VERUPADUGAL 
 Our siddha system is based on the three humoral theory. The three humors of 
siddha medicine are called by different terminologies, namely Uyirthathu, Thosham, 
Kutrams. They are, 
 Vali - Air and Space 
 Azhal - Fire 
 Iyam - Earth and Water 
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Each of them has different functions. Whey they are in equilibrium, a normal 
structural and physiological state of the body is ensured. When the humors are disturbed, 
it manifests a pathological state of the body. 
 
  ‘kpfpDq; FiwapDk; Neha; nra;Ak; E}Nyhh; 
  tsp Kjyh ntz;zpa %d;W” (Fws;) 
 
In Swasa Erumal, the factors such as diet, habit, environment etc., adversely 
influence on Iyam and Vali to cause this disease. The involvement of Udana vayu plays a 
vital role in the manifestation of signs and symptoms. 
 
  ‘fgj;jpid ad;wpf; fhrRthrq; - fhzhJ” 
     -   Njiuahh; (Neha; ehly; jpul;L 1 340 
MUKKUTRA VAERUPADUGAL :( Pathogenesis) 
Disease occurs due to the derangement in 
•  Uyir thathukkal  
•  Udalthathukkal   
•  kala marupadu(seasonal changes) 
• Thinai( living lands ) and 
• Udal vanmai. 
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UYIR THATHUKKAL: 
Mukkutra Iyal : 
The function of the three uyir thathus:  
a) Vali   –  (Kattru + Veli) 
 
b) Azhal   – (Thee) 
 
c) Iyyam   – (Neer+Mann) 
 
The alteration of three thathu in their reaction to extrinsic or intrinsic factors 
results in disharmony. This altered harmony and balance variation of the three thathus 
results in disease. Their natural ratio (1 :½:¼) to each other is discerned by the physician 
at the wrist and each nadi is individually assessed for its strength, speed and regularity. 
The following poem describes the origin of three Uyir Thathus 
  ‘,Ug;ghd ehb vOgNjhBuh 
 apukhd Njfj;jpy; Vyg; -ngUehb 
 xf;fj; jrkj; njhopiy a+f;f jrthAf;fs; 
 jf;fgbahdNj  rhu;G” 
 
‘rhUe; jrehb jd;dpy; %yk; %d;W 
 NgUkplkp gpq;fiyAk; gpd;dYld;-  khWk;  
 ciuf;ftpuw; fhw;nwhl;Lzu;j;J Nkehrp 
 tiur;Rop Nahikaj;jpy; te;J” 
 
‘te;jfiy %d;wpy; tha;thkghdDld; 
 je;j gpuhzd; rkhdDk; re;jKwf; 
27 
   
 $l;Lwtpy; Nurpj;jy; $Wk; thjk; gpj;jk;; 
 ehl;Lq;fgNk ahk; ehL” 
 
- fz;Zrhkpak;- gf;fk; 36 
  The three Thathus are manifested at the wrist and are individually and collectively 
assessed. These three humour are divided in to various types and have their functions 
specifically. 
FUNCTIONS OF VALI:  
 
‘xOq;Fls; jhNjo;%r; Nrhq;fp ,aq;f 
vOr;rpngw vg;gzpAk; Mw;w - vOe;fpupa 
Ntfk; Gyd;fSf;F Nktr; RWRWg;G 
thfspf;Fk; khe;ju;f;F thA” 
 
- kUj;Jt jdpg;ghly;  gf;fk;12 
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According to the physiological function, vali is ten types. They are  
S.NO VATHAM GENERAL FEATURES 
CHANGES IN 
SWASA KASAM  
1. Piranan(Uyir Kaal)  
Responsible for 
respiration and it is 
necessary for proper 
digestion  
 
Affected 
2. Abanan(Kizhnokkumkaal) 
Responsible for  all 
downward forces such as 
voiding of urine, stools, 
semen, menstrual flow  
 
Normal 
3. Viyanan(paravukaal) 
Dwells in the skin and is 
concerned with the sense 
of touch... extension and 
flexion of the parts of the 
body and distribution, of 
the nutrients to various 
parts of the body 
 
Affected 
4. Uthanan (melnokkukaal) 
Responsible for all kinds 
of upward motion such as 
nausea, vomiting etc... 
 
Affected 
5. Samanan(nadukkaal) 
Considered essential for 
proper digestion, 
assimilation and carries 
the digested nutrients to 
each and every organ 
 
Affected 
6. Nagan  
Helps in opening 
&closing of eyelids 
 
 
Normal 
7. Koorman  
Responsible for vision, 
lacrimation  and yawning 
 
Normal 
8. Kirugaran 
Induces  appetite, 
salivation, all secretions in 
the body including nasal 
Affected 
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secretion and sneezing 
 
9. Thevathathan  
Induces and stimulates a 
person to become alert, 
get anger, to quarrel, to 
sleep etc 
 
Affected 
10. Dhananjeyan  
Resides in the cranium 
and produces bloating of 
the body after death. This 
leaves from the body after 
3days of death, forming a 
way through the skull. 
- 
 
In Swasa kasam, Prananan, uthanan, Viyanan,,kirugaran, devathathan will be mainly 
affected. 
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FUNTIONS OF AZHAL: 
 
 ‘grpjhfk; Xq;nfhspfz; ghu;itgz; lj;J 
 Urpnjup rj;jp ntk;ik tPuk; - crpj 
 kjp$u;j;j Gj;jptdg; gspj;Jf; fhf;Fk; 
 mjpfhup ahq;fh doy;” 
-  kUj;Jt jdpg;ghly; gf;fk;16 
Azhal is functionally divided in to five types. They are 
 
In Swasa kasam, Anila pitham, Sathaga pitham will be mainly affected 
S.NO PITHAM NORMAL FEATURES 
CHANGES IN 
SWASA KASAM 
1. Anarpitham(Akkuanal) Peps up the appetite and aids in digestion. Affected 
2. Ranjagapitham(Vanna eri) Responsible for the color and contents of blood. Normal 
3. Sathagapitham(Attralangi) 
Controls the whole body 
and is held responsible for 
fulfilling a purpose. 
Affected 
4. Pirasagapitham(Ollolithee)  
Dwells in the skin and 
concerned with the shine, 
glow, texture and its 
complexion 
Normal 
5. Alosagapitham(Nokku Azhal) 
Responsible for the 
perception of vision. Normal 
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FUNTIONS OF IYAM: 
‘jplkPA nkd;gpizg;Gj; jpz;ikAw;w ahg;Gk; 
mlNyu; tOtOg;Gk; Mf;iff; - fplu;f;F 
ntUthg; nghWikAk; Nkyhd fhg;ghk; 
ngUikj;jh ikankdg; NgR” 
- kUj;Jt jdpg;ghly; gf;fk;20 
It is of five types. They are 
 
In Swasa kasam, Avalambagam and kilethagam may be affected.     
S.NO KABHAM GENERAL FEATURES CHANGES IN SWASA KASAM 
1. Avalambagam(Alli Iyyam)  
Lies in the respiratory organs, 
exercises authority over other 
khapas and controls the heart 
and circulatory system. 
Affected 
2. Kilethagam(Neerpi Iyyam)  
Found in stomach as its seat, 
moistens the food, softens and 
helps to be digested. 
Affected 
3. Pothagam(Suvaikanna Iyyam)  
Hold responsible for the 
sensory perception of taste. 
Normal 
4. 
 
 
Tharpagam(Niraivu 
Iyyam)  
Presents in the head and is 
responsible for the coolness of 
the eyes, sometimes may be 
referred to as cerebrospinal 
fluid 
Normal 
5. Santhigam(Ondri Iyyam)  
Necessary for the lubrication 
and the free movements of 
joints. 
Normal 
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UDAL KOORUGAL (SEVEN PHYSICAL CONSTITUENTS): 
‘,ukpuj; je;jir nea; epznkd;G kr;irtPe;njd;NwOk; KiwNa” 
 rujnkhL nka;kdj;J epiwTjUk;capUl;Lj;jhq;fp apUf;Fk; 
 cuKjTk; NkLgs;sk; epuTk; nea;g; gira+l;Lk; Xq;fp epWj;Jk;  
 gue;njd;gpd; JisfnlhWk; epuk;gpLq;fs; KisNjhd;wg; gz;Zk; njuptha;” 
       -rpj;j kUj;J}thq;fr; RUf;fk; -gf;fk;334 
The human body is made of seven basic physical constituents. These constituents 
should be in harmony and function normally. Any variation in them will lead to their 
functional deviations. 
The Natural characters of the seven physical constituents 
S.NO UDAL KATTUGAL GENERAL FEATURES 
CHANGES IN 
SWASA 
KASAM 
1. 
Saaram 
 (digestive essence) 
Responsible for the growth& 
development. It keeps the 
individual in good 
temperament and it enriches 
the bood. 
Affected 
2. Senneer (blood) 
Responsible for the colour of 
blood and for the intellect, 
nourishment, strength, vigour 
and valour of the body.  
Normal 
3. Oon (muscle) 
Gives lookable contour to the 
body as needed for the 
physical activity. It feed the fat 
next day and gives a sort of 
plumpness to the body  
Normal 
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4. Kozhuppu (fat) 
Lubricates the organs to 
facilitate frictionless functions. 
Normal 
5. Enbu (bones) 
Supports & protects the vital 
organs, gives the definite 
structure of the body and 
responsible for the posture and 
movements of the body 
Normal 
6. Moolai (bone marrow) 
Nourishes the bone marrow 
and brain which is the centre 
that controls other systems of 
body 
Normal 
7. Sukkilam/ Suronitham(sperm/ ova) 
Responsible for reproduction Normal 
 
THE VARIATIONS OF THE PHYSICAL CONSTITUENTS: 
1. SAARAM  
           Increased Saaram:Leads to diseases of increased kapham like indigestion Etc 
            Decreased Saaram : Leads to loss of weight, tiredness, lassitude, dryness of the 
skin and diminished activity of the sense organs. 
2. SENNER 
 Increased Senner : Causes boils in different parts of the body throbbing pain, 
anorexia, mental disorder, splenomegaly, Colicky pain., increased blood pressure, reddish 
eye and   Skin, jaundice, haematuria etc. 
 Decreased Senner : Leads to anaemia, tiredness, neuritis and lassitude, Pallor of 
body. 
3. OON  
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 Increased Oon : Oon in excess causes cervical lymph adenitis, venereal ulcer, 
tumour in face, abdomen, thigh genitalia etc are the signs of increased Oon 
 Decreased Oon : Leads to impairment of sense organs, joints jaw, thigh and 
genitalia gets shortened 
4. KOZHUPPU 
 Increased Kozhuppu: Identical to that of increased Oon associated with Dyspnoea 
and loss of acidity 
 Decreased Kozhuppu: Leads to pain in the hip region and diseases of the spleen 
5. ENBU 
 Excess Enbu : Growth in bones and teeth 
 Decreased Enbu : Loosening of teeth and nails and Splitting and falling of hair 
6. MOOLAI 
 Increased Moolai : Causes heaviness, swollen eyes, swollen phalanges, Oliguria 
and non healing ulcers 
 Decreased Moolai : Causes osteoporosis and sunken eyes 
7. SUKKILAM / SURONITHAM 
 Excess Sukkilam/Suronitham : Causes lust towards women and cause Urinary 
calculus 
 Decreased Sukkilam/Suronitham : Causes failure in reproduction, pain in the 
genitalia. 
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KAALA MARUBADUGAL: 
PARUVAKALAM (SEASONS): 
              According to ancient tamilians, the one year is divided in to six seasons and each 
season consists of two months and the year starts from Margazhi. 
S.NO KAALAM TAMIL MONTHS MUKKUTTRA   
MARUPAADUGAL 
1. Kaar Kaalam Aavani & Purattasi 
Aug 16 To Oct15 
VATHAM-Vettunilai 
Vazharchi 
PITHAM-Thanilai Vazharchi 
2. Koothir Kaalam Iypasi &Karthigai 
Oct 16 To  Dec15 
VATHAM- Thanilai Vazharchi 
PITHAM- Vettunilai 
Vazharchi 
3. Munpani Kaalam Margazhi & Thai 
Dec16 To Feb15 PITHAM- Thanilai Vazharchi 
4. Pinpani Kaalam Masi& Panguni 
Feb16 To June15 
KABHAM- Thanilai 
Vazharchi 
5. Elavenir Kaalam Chithirai & Vaikaasi 
April16 To June15 
KABHAM- Vettunilai 
Vazharchi 
6. Mudhuvenir Kaalam Aani & Aadi 
June16 To Aug 15 VATHAM- Thanilai Vazharchi 
 
 
THINAI (LAND): 
            Siddhars classified the lands in to five types. They are 
1. Kurunchi    - Mountain range 
2. Mullai         -Pastoral area of the forest 
3. Marudham -The fertile river bed 
4. Neidhal      -The coastal region 
5. Paalai         - Arid desert                                               
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• The winter season gives good health to the man, early summer and latter rainy 
gives moderate health. Whereas early rainy and latter summer are more prone to 
diseases, that’s why siddhars called it as Aanaga kalam 
• Marudha nilam is the fertile area where no disease occurs 
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RELATION BETWEEN MUKKUTRAM, KAALANGAL AND THINNAIGAL                                                                                                                                                                         
 
  
MUKKUTRAM 
               PARUVAKALAM(SEASONS)                  
THINAI                         
Thannilai 
vazharchi 
(Accumulation) 
Vaetrunilai 
vazharchi        
(Aggravation) 
Thannilai 
adaithal             
(Alleviation) 
 
 
VATHAM 
 
 
Mudhuvenil 
kalam 
 
 
Kaar kalam 
 
 
 
 
Koothir kalam 
 
 
Vatha disease 
is more 
prevalent in 
Neidhal land 
 
 
PITHAM 
 
 
Kaar kalam 
 
 
Koothir kalam 
 
 
Munpani 
Pitha disease 
is more 
prevalent in 
Mullai land 
 
 
KAPHAM 
 
 
Pinpani 
 
 
Elavenil kalam 
 
 
Mudhuvenil 
kalam 
Kaphadisease 
is more 
prevalent in  
Kurunchi 
land 
 
38 
   
 
  UDAL VANMAI (IMMUNITY): 
            Siddhars classify Udal vanmai as three types. They are 
1. Iyarkai vanmai 
2. Kala vanmai 
3. Seyarkai vanmai 
 
PINIYARI MURAIMAI (DIAGNOSIS): 
           It means the method of diagnosing the disease.           
         ‘kjpj;jplw;fUik tha;e;j 
                   khz;gupfhunky;yhe; 
            Jjpj;jpl Tzu;e;jhNdDe; 
                  Jfswg; gzpapd;wd;ik 
            gjpj;jpl Tzuhdhfpw; 
                  gaDwhdhfhyhNd 
            tpjpj;jpL gpzpj;jpwj;ij 
                  tpsk;GJ Kjw;fz;kd;Ndh” 
 
- rpfpr;rh uj;jpdjPgk;- gf;fk; 3    
                                      
              The above poem describes that diagnosis is very important for the physician to 
treat the disease. 
 
 
 
And, 
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§¿¡ÂÈ¢óÐ §¿¡ö Ó¾Ä¢ §¿¡ì¸È¢óÐ §¿¡Ô¾ý 
¾¡ÂÈ¢óÐ §À¡ìÌó ¾¡ÁÈ¢óÐ ¸¡Â¿¢¨Ä 
¦¿¡ó¾Æ¢Â¡ Åñ½ ¸÷Å¢ôÀ¡÷ §¿¡Â¢É÷ìÌ 
¾ó¨¾¦ÂÐ ¿üÀñÊ¾÷ 
-§¾Ãý ¦ÅñÀ¡ 
 
Four steps are followed in diagnosing the disease. They are, 
a. Poriyaal arithal 
b. Pulanal therthal 
c. Vinaathal 
d. Envagaithervu  
In detail, 
 
a. Poriyaal arithal: 
                     In this the physician should carefully observe the changes that occur in the 
five sensory organs (Porigal) of the patient. 
 
b.Pulanal therthal: 
                 The physician carefully applies his five senses of perception, smell, taste, 
vision, touch and sound to understand the condition of the patient. 
c.Vinaathal: 
                 The physician should interrogate about the patients name, age, 
occupation,socio economic status, food habits, history of past illness, history of present 
illness, family history, marital status, menstrual history and frequency of pain. 
 
ENVAGAI THERVUKAL 
‘eh epwk; nkhop tpop ky%j;jpuk; 
 ehb guprkpit kUj;JtuhAjk;” 
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-Neha;ehly; Neha; Kjdhly;-253 
 
 
¿¡ÊÂ¡ø Óý§É¡÷ ¦º¡ýÉ ¿ø¦Ä¡Ä¢ À¡¢ºò¾¡Öõ 
¿£ÊÂ Å¢Æ¢Â¢É¡Öõ ¿¢ýÈ ¿¡ìÌÈ¢ôÀ¢É¡Öõ 
Å¡ÊÂ §ÁÉ¢Â¡Öõ ÁÄ¦Á¡Î ¿£¡¢É¡Öõ 
ÝÊÂ Å¢Â¡¾¢¾ý¨Éî Í¸Ó¼ý «È¢óòÐÀ¡§Ã 
- ¾¢ÕÁó¾¢Ãõ - 10õ ¾¢ÕÁ¨È 
                     
 Nowadays advanced diagnostic tools have been developed by modern bio-
medical scientists. But Siddhars have given eight diagnostic methodological tools. They 
are called as Envagai thervu. 
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Eight fold system of clinical assessments: 
Siddhars have given eight diagnostic methodological tools. They are, 
 
1. Naa 
2. Niram 
3. Mozhi 
4. Vizhi 
5. Malam 
6. Moothiram 
7. Naadi 
8. Parisam 
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GENERAL FINDINGS: 
1. NAA: 
i. Signs and symptoms in the tongue are noted here. 
ii. Color, salivary secretion, ulcers, coating, inflammation, 
taste changes, deviation and its nature are generally noted. 
       In Swasa kasam the naa may be affected due to coated tongue 
2. NIRAM: 
The color of the skin is noted here. 
          In Swasa kasam the niram may be affected due to the pallor of the 
body. 
3.  MOZHI: 
Character of the speech is noted, mainly uratha olli(high 
pitched), thazhntha olli(low pitched), or resembles the 
sound of any instrument. 
In Swasa kasam the mozhi will be affected due to breathlessness. 
4. VIZHI: 
Character of the eye is noted. Color, Warm, Burning 
Sensation, Irritation, Visual Perception.   
     In Swasa kasam the vizhi may be pale. 
5. MALAM: 
The stools are examined for quantity; hardening 
(malakattu), loose motion (bethi), Color and smell. 
     In Swasa kasam the malam will be affected in elderly patients due to 
constipation.
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    6. MOOTHIRAM: 
    A. NEERKURI: 
The urine is examined for its color, odour, volume, froth 
and weight. 
 In Swasa kasam the moothiram will not be affected. 
    B.NEIKURI 
‘mUe;J khwp ujKk; mtpNuhjkjha;  
  mf;fy; myu;jy;mfhyt+d; jtpu;jow; 
 Fw;wstUe;jp cwq;fp itfiw 
 Mbf;fyrj; jhtpNa fhJnga; 
 njhUK$u;j;jf; fiyf;Fl;gL ePupd; 
 epwf;Fwp nea;Fwp epUkpj;jy; flNd” 
       -rpj;j kUj;Jthq;fr; RUf;fk; - 
gf;fk;509  
                      
              The early morning urine of the patient is analyzed by dropping a drop 
of gingely oil on the surface of the urine sample. The accumulation, 
formations, changes, and dispersal under the sunlight without any external 
disturbances of the urine sample can be noted.  
• Vatha neer - The oil spreads like snake 
• Pitha neer - The oil spreads like ring 
• Kapha neer - The oil spreads like pearl 
• If the oil spreads gradually, it indicates good prognosis 
• If the oil spreads fast or gets mixed completely with urine or sinks in 
urine, it suggests bad prognosis. 
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Since Swasa kasam is due to the derangement of vatham and kapam,the 
neikuri will be vatha or kapa neer. 
7. NAADI: 
             Naadi is a Unique Siddha Pulse reading method and it should be felt 
and not read. Different gaits of Vazhi , Azhal, Iyam  like branching, jumping, 
mixing, rotating and compression can be identified. 
NAADI NADAI: 
 
     ‘ghu;f;fNt ngz;fSf; fplJgf;fk; 
      gjpthfg; ghu;j;jplNt gfugf;NfSk; 
      fhu;fNt thjkJ ru;g;gk; Nghyha; 
      fdkhd gpj;jkJ jtis NghyhQ; 
      Nru;f;fNt iaankd;w ehbjhDQ; 
      rpWeilah td;dk; Nghw; nropg;gha;f; fhDk;” 
-gjpnzd; rpj;ju; ehbrhj;jpuk; (gupG+uz ehb)-  
gf;fk;2 
 
In Swasa kasam  patients following types of nadai are seen commonly; 
 
IDENTIFICATION 
(FINGER) 
 
INDEX 
 
MIDDLE 
 
RING 
 
STRENGTH (IN UNIT) 
 
1 
 
1|2 
 
1|4 
 
 
PATTERN 
 
 
 
MALE 
 
Hen 
 
Tortoise 
 
Snake 
 
FEMALE 
 
Snake 
 
Frog 
 
Swan 
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o Iya naadi is increased. 
o Vali iyam 
 
8. PARISAM:  
Observations as touch, temperature, sensory impairment, masses, nodes, 
swelling, and texture of the skin, pain, hardness, edematous, and dullness shall 
be noted. 
 
In Swasa kasam the patients body is heat or cold is noted. 
 
LINE OF TREATMENT: 
1. Since Swasa kasam is a Kapha disease, Mild laxative is given to balance the 
Kapham. 
 
2.MEDICINE: 
 For Treatment: 
I. Linga  mathirai 
- one tablet, Twice Daily. 
- With Water. 
 
3. DURATION OF TREATMENT: 
48 ays medicine, 
 
 
4. ADVICE: 
• To follow good personal hygiene 
• Avoid chill and cold weather 
• To avoid exposure to dust, fumes and smokes 
• To avoid smoking 
• To find out allergen and avoid them 
• Advise to practice pranayamam and yoga.  
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5. .Yoga practice 
o Pujangasanam 
o Sarvangasanam 
o Patchimothasanam 
o Salabasanam 
o machasanam 
6. PREVENTION: 
•  Balanced & Low fat diet 
• Regular exercise 
• Suriya namesakaram 
• Oil bath twice in a week 
• Avoid Junk foods 
• Avoid tobacco, Alcohol 
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MODERN ASPECTS 
ANATOMY OF RESPIRATORY SYSTEM: 
              The respiratory system is meant primarily, for the oxygenation of 
blood. Developmentally the respiratory system is an outgrowth from the ventral 
wall of the foregut. 
             The organs of respiratory system are nose, pharynx, larynx, trachea, 
two bronchi (one bronchus to each lung), bronchioles and smaller air passages, 
two lungs and their coverings-the pleura, muscles of respiration-the intercostal 
muscle and the diaphragm. 
            The upper respiratory tract includes the nose, nasopharynx, and larynx. 
It is lined with ciliated epithelium on their surfaces.  
            The lower respiratory tract includes the trachea and bronchi. These 
form an interconnecting tree of the conducting airways eventually joining, via 
64000 terminal bronchioles, with alveoli to form the acini. The lower 
respiratory tract is lined with ciliated epithelium as far as the terminal 
bronchioles 
TRACHEA: 
           It is a membrano-cartilaginous tube which forms the upper part of the 
lower respiratory tract and convey air from larynx through trachea into the 
lungs via bronchus. 
EXTENT: 
Begins as a continuation of lower border of the cricoid cartilage at the 
level of 6th cervical vertebra. 
           End by dividing into two bronchi Right and left at the level of lower 
border of the body of the fourth thoracic vertebra. 
 
DIMENSION: 
           Length   -   10 to 11cm 
 External Transverse diameter 
            In adult Male - 2cm 
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In adult female  -1.5cm 
Antero posterior diameter - about 12mm. 
SHAPE: 
          It is a tubular structure with a flattened posterior wall. 
PARTS: 
 Cervical part  
 Thoracic part 
HISTOLOGY: 
 Outer fibrous layer 
 Cartilage rings (16 to 20) of hyaline type and deficient posteriorly where 
the smooth muscle trachealis fills the gap. In between the adjoining 
tracheal rings, is a fibro elastic membrane. 
 Sub mucous coat is made of loose connective tissue with large blood  
vessels, nerves, and mucous glands. 
 Mucous membrane is lined by pseudo stratified ciliated columnar 
epithelium with globlet cells in between. The epithelium rests on the 
basement membrane. 
 
 
FUNCTIONS: 
• Support and potency 
• Mucociliary escalator 
• Cough reflex 
BLOOD SUPPLY: 
 Arteries: 
 Inferior thyroid arteries 
 Bronchial arteries 
 Veins: 
 Inferior thyroid venous plexus. 
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LYMPHATICS: 
 Pre tracheal lymph nodes 
 Para tracheal lymph nodes 
 
NERVE SUPPLY: 
 Laryngeal parasympathetic: 
• Right and left vagus nerve 
• Recurrent laryngeal nerve 
 Sympathetic: 
• From upper 4th or 5th Thoracic segment of the spinal 
cord. 
        Supply trachealis muscle and the mucous membrane. 
 
 
BRONCHI: 
         The two bronchi are formed by the bifurcation of the trachea at the level 
of the lower border of the body of the 4th thoracic vertebra. 
        The right bronchus is wider and shorter tube than the left bronchus and it 
lies in a more vertical position. It is approximately 2.5cm long. After entering 
the right lung at the hilum, it divides into three branches, one of which passes 
to each lobe. Each branches then subdivided into numerous smaller branches. 
       The left bronchus is about 5cm long and is narrower than the right. After 
entering the lung at the hilum, it divides into two branches, one of which passes 
to each lobe. Each branch then subdivides progressively into smaller tubes 
within the lung. 
FUNCTIONS: 
• Warming and humidifying 
• Support and potency 
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• Removal of particulate matter 
• Cough reflex 
BLOOD SUPPLY: 
Arteries: 
        Right and left bronchial arteries 
Veins: 
        Bronchial veins 
 
LYMPHATIC SUPPLY: 
     Lymph passes through lymph nodes around the trachea and bronchial 
tree, then into the thoracic duct on the left side, and the right lymphatic duct on 
the other side. 
 
 
NERVE SUPPLY: 
          The nerve supply is by parasympathetic and sympathetic nerves. The 
vagusnerve (Parasympathetic) stimulate contraction of smooth muscles in the 
bronchial tree, causing bronchoconstriction and sumpathetic stimulation causes 
bronchodilation. 
LUNGS: 
          They are the essential organs of respiratory system. The right and left 
lungs lies in the corresponding halves of the thorax. They are separated from 
each other by structures in the mediastinum. 
Colour: 
Children - Pink 
  Adult       - Dark grey mottled due to inhalation dust and carbon particles. 
Shape: 
    Conical in shape 
Consistency: 
    Soft and spongy 
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Parts of the lung: 
Apex: 
       Each lung has a relatively narrow upper end, and it rises into the root of the 
neck about 25mm above the level of the middle one third of the clavicle. 
Surfaces of the lung: 
Inferior surface or Base – Concave and semilunar in shape 
Costal surface – Convex and is closely associated with costal cartilages, the 
ribs, and the intercostal muscles. 
Medial surface – Concave and has aroughly triangular shaped area called 
hilum, at the level of 5th, 6th, 7th thoracic vertebra. Structures which form the 
root of the lung enter and leave at the hilum. 
       The area between the lungs is mediastinum. It is occupied by the heart, 
great vessels, trachea, right and left bronchi, oesophagus, lymph vessels and 
nerves. 
Fissures and lobes: 
Right lung  
      The right lung is slightly larger than the left and is divided by the oblique 
and horizontal fissures into three lobes namely 
        Upper lobe 
        Middle lobe 
         Lower lobe 
 
Oblique fissure: 
            The oblique fissure runs runs from the inferior border upward and 
backward across the medial and costal surfaces until it cuts the posterior border 
about 2½ inches below the apex. 
Horizontal fissure: 
          The horizontal fissure runs horizontally across the costal surface at the 
level of the 4th costal cartilage to meet the oblique fissure in the midaxillary 
line. 
Left lung: 
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         The left lung is divided by a similar oblique fissure into two lobes, the 
upper and the lower lobe. There is no horizontal fissure in the left lung. 
 
Broncho Pulmonary segments: 
         The broncho pulmonary segments are the anatomical, functional and 
surgical units of the lungs. Each lobar bronchus which passes to a lobe of the 
lung,gives of branches called segmental bronchi. Each segmental bronchus 
then enters a broncho pulmonary segment. A bronchopulmonary segment has 
the following characteristics. 
It is a sub division of a lung lobe 
It is pyramidal in shape with its apex towards the lung root 
It is surrounded by connective tissue 
It has asegmental bronchus, a segmental artery, lymph vessels, and 
autonomic nerves. 
The segmental vein lies in the connective tissue between adjacent 
broncho pulmonary segments. 
A diseased segment, since it is a structural unit. Can be removed 
surgically. 
            
 The main broncho pulmonary segments are as follows: 
Right lung: 
Superior lobe: 
• Apical 
• Posterior 
• Anterior 
  Middle lobe: 
• Lateral 
• Medial 
Inferior lobe: 
• Superior(Apical) 
• Medial basal 
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• Anterior basl 
• Lateral basa 
• Posterior basal 
Left lung: 
Superior lobe: 
• Apical 
• Anterior 
• Posterior 
• Superior lingual 
• Inferior lingual 
Inferior lobe: 
• Superior (Apical) 
• Medial basal 
• Anterior basal 
• Lateral basal 
• Posterior basal 
Blood supply: 
Pulmonary artery 
      It carries deoxygenated blood from right ventricle to the lungs for 
oxygenation. It ends in the capillary plexus on the alveolar wall of the lung. 
Pulmonary veins: 
      Two lungs emerge from the hilum of each lung empty into the left atrium. 
They start from the alveolar capillaries and carry the oxygenated blood from 
the lungs to the heart. 
Bronchial artery: 
      It is a direct branch from the descending thoracic aorta and supplies the 
bronchial tree as far as the respiratory bronchioles. 
Lymphatic drainage: 
• Superficial 
• Deep 
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     The superficial lymphatics lie beneath the visceral pleura, while the deep 
lymphatics follow the ramification of the bronchi and the pulmonary arteries. 
Both sets of lymphatics end in the broncho pulmonary nodes situated in the 
hilum of the lung. 
Nerve supply: 
    There are two nerve plexuses. Anterior and posterior pulmonary plexuses, 
situated on the respective sides of the root of the lung. The plexus consists of 
both para sympathetic (derived from vagi) and sympathetic (derived from 2nd, 
3rd, and 4th thoracic sympathetic ganglia) fibres. 
Histology:  
      Thin alveolar septa separate the alveolar spaces. The septa are lined by thin 
flattened alveolar cells with a capillary network of blood vessels on theirwall. 
Electron microscopic studies show that the blood in the capillaries and the air 
in the alveoli are separated by a thin continuous layer of alveolar epithelium 
and capillary endothelium with two layers of basement membrane in between 
them. Many alveolar cells are phagocytic. 
     Each section of intrapulmonary bronchi show an outer fibrous coat with 
irregular plates of hyaline cartilage, middle bronchial muscle fibres and inner 
mucous membrane which is lined by a layer of ciliated columnar epithelium, 
on its inner surface with lymphoid tissue, longitudinal elastic fibres and 
mucous secreting glands outer to the epithelium. 
      The terminal or respiratory bronchioles are about 3.2mm in diameter and 
have no cartilage in their walls. Simple non-ciliated cubical epithelium lines 
their lumen. 
Pleura: 
Each lung is enclosed by a bilayered serous called pleura or pleural sac. The 
two layers of pleura are the visceral and parietal layers. Visceral (inner) layer is 
attached firmly to the surface of the lungs. At hilum, it is continuous with 
parietal (outer) layer, which is attached to the wall of the thoracic cavity. 
           The narrow space in between the two layers of pleura is called 
intrapleural space or pleural cavity. This space contains a thin film of serous 
56 
   
fluid called pleural fluid. It is secreted by the visceral layer of the pleura. It 
functions as the lubricant to prevent friction between two layers. It is involved 
in creating negative pressure called intrapleural pressure within intrapleural 
space.  
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PHYSIOLOGY OF RESPIRATORY SYSTEM 
Allergy & Immunology 
Mast cells and Basophills: 
       Mast cells and Baso phills are derived from Bone marrow which plays a 
vital role in allergic disorders. Mast cells reside predominantly in tissues 
exposed to the external environment, such as skin and gut, while Basophills are 
located in the circulation and are recruited into tissues in response to 
inflammation. Both contain large cytoplasmic granules which enclose 
performed vasoactive substances such as histamine. Additional mediators are 
synthesized de novo after activation, including leukotrienes, prostaglandins, 
and cytokines. Local release of these mediators initiate an inflammatory 
cascade which increases local blood flow and vascular permeability, stimulates 
smooth muscle contraction, and increases secretion at mucosal surfaces.  
          Normally the immune system does not make detectable response to many 
environmental substances such as foods and inhaled particles to which it 
exposed on a daily basis. In an allergic reaction, initial exposure to an 
otherwise harmless exogenous substance (or allergen) triggers the production 
of specific IgE antibodies by activated B cells. These are bound to the surfaces 
of mast cells via high affinity IgE receptors, a step that is not immediately 
associated with clinical sequelae.   
           However, upon re-exposure, the allergen binds to membrane-bound IgE 
which activates the mast cells. These release a variety of vasoactive mediators 
(the early phase response) like histamine causing a type I hypersensitivity 
reaction and the symptoms of allergy. These range from Sneezing and 
Rhinorrhoea to anaphylaxsis.  
         Persistant activation of Mast cells results in the recruitment of other cells 
to the site of release.  In some patients, the early phase response is followed 4-8 
hours later by persistant swelling and local inflammation. This is known as late 
phase reaction and is mediated by Basophills, eosinophills, and Macrophages 
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Long standing or recurrent allergic inflammation may give rise to a chronic 
inflammatory response characterized by a complex infiltrate of macrophages, 
eosinophills, T Lymphocytes in addition to mast cells and Basophills. 
RESPIRATION: 
        Respiration is the process by which oxygen is taken in and carbon dioxide 
is given out. 
Muscles of Respiration 
Classified into two types 
I. Primary Respiratory muscles: 
Responsible for change in size of the thoracic cage during normal quiet 
breathing. 
a) Primary inspiratory muscle 
Diaphragm supplied by phrenic nerve (C3 – C5) 
External intercostal muscle supplied by intercostal nerves (T1 – 
T11) 
b) Primary expiratory muscle 
Internal intercostal muscles innervated by intercostal nerves. 
II. Accessary Respiratory muscle: 
Help Primary respiratory muscle during forced respiration. 
a. Accessary inspiratory muscle 
    Sternocleidomastoid 
     Scaleni 
Anterior serrati 
Elevators of scapulae 
Pectoralis 
b. Accessary expiratory muscle 
Abdominal muscle 
Movement of thoracic cage 
Inspiration causes enlargement of thoracic cage, which occurs because of the 
movements of four units of structures, 
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a) Thoracic Lid: 
Formed by manubrium sterni and the first pair of ribs. Due to 
contraction of scalene muscles, the first rib move upwards to a more 
horizontal position. This increases the anteroposterior diameter of the 
thoracic cage.  
b) Upper costal series: 
Increases the anteroposterior and transverse diameter of the thoracic 
cage. 
c) Lower costal series: 
Increases the transverse diameter of the thoracic cage. 
d) Diaphragm: 
       During inspiration, central portion of the Dome shaped diaphragm 
is drawn downwards. So the diaphragm is flattened, which increases the 
vertical diameter of the thoracic cage. 
Movements of Lungs 
During inspiration, due to enlargement of the thoracic cage, the negative 
pressure is increased in the thoracic cavity. It causes expansion of the lungs. 
              During expiration, the thoracic cavity decreases in size  to the 
preinspiratory position. The pressure in the thoracic cage also comes back to 
the preinspiratory level. It compresses the lung tissues so that, the air is 
expelled out of lungs. 
Respiratory Pressures: 
          Two types of pressures are exerted in the thoracic cavity and the lungs 
during the process of respiration 
 
A) Intrapleural pressure or intrathoracic pressure: 
         It is the pressure existing in between the visceral and parietal layers of the 
pleura. It is exerted by the suction of the fluid that lines the pleural cavity. 
Significance of Intrapleural Pressure 
Throughout the respiratory cycle intrapleural pressure remains lower than intra-
alveolar pressure. 
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I. Since the intrapleural pressure is always negative, it prevents the 
collapsing tendency of lungs, which is caused by elastic recoiling of 
lung tissues. 
II. Because of the negative pressure in thoracic region, the larger veins and 
vena cava are enlarged, i.e. dilated. Also, the negative pressure acts like 
suction pump and pulls the venous blood from lower part of the body 
towards the heart against gravity. Thus the intrapleural pressure is 
responsible for the venous return. 
B) Intra-alveolar pressure or intrapulmonary pressure: 
       It is the pressure existing in the alveoli of the lungs. 
Significance of Intra-alveolar pressure 
I. The intra-alveolar pressure causes flow of air in and out of alveoli. 
During inspiration, the intra-alveolar pressure becomes negative, So the 
atmospheric air enters the alveoli. During expiration, the Intra-alveolar 
pressure becomes positive, so the air is expelled out of alveoli. 
II. The intra-alveolar pressure also helps in the exchange of gases between 
the alveolar air and the blood. 
III. Exchange of Respiratory Gases: 
      In the lungs exchange of respiratory gases takes place between the alveoli 
and the blood. The exchange of gases occurs through bulk flow diffusion.  
      Respiratory unit is the structure through which the exchange of gases 
between blood and alveoli takes place. 
Respiratory membrane: 
The respiratory membrane is formed by the epithelium of the respiratory 
unit and endothelium of the pulmonary capillary. The epithelium of the 
respiratory unit is a very thin layer. As the capillaries are in close 
contact with this membrane, the alveolar air is in close proximity to 
capillary blood. This facilitates the gaseous exchange between air and 
blood. 
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Diffusion of oxygen: 
Diffusion of atmospheric air into the alveoli 
The partial pressure of oxygen in the atmospheric air is 159mmHg and in the 
alveoli it is 104mmHg. Because of the pressure gradient of 55mmHg, oxygen 
easily enters from atmospheric air into the alveoli 
Diffusion of oxygen from alveoli into the blood 
             When the blood is flowing through the pulmonary capillary, RBC 
exposed to oxygen only for 0.7 sec at rest and only for 0.25 sec during severe 
exercise. So the diffusion of oxygen must be quicker and effective. Fortunately 
this is because of the pressure gradient. 
            The partial pressure of oxygen in the pulmonary capillary is 40mmHg 
and in the alveoli, it is 104mmHg. It facilitates the diffusion from alveoli into 
the blood. 
Diffusion of carbondioxide: 
Diffusion of Carbon dioxide from blood into alveoli:The partial pressure of 
carbon dioxide in alveoli is 40mmHg whereas in the blood it is 46mmHg. The 
pressure gradient of 6mmHg is responsible for the diffusion of carbon dioxide 
from the blood into the alveoli. 
Diffusion of carbon dioxide from alveoli into the atmospheric air: 
  In the atmospheric air, the partial pressure of carbon dioxide is very 
insignificant and is only about 0.3mmHg Whereas in the alveoli, it is 40mmHg. 
So the carbon dioxide enters the atmosphere from alveoli easily.  
Exchange of gases at tissue level: 
Diffusion of oxygen from blood into the tissues: 
The partial pressure of oxygen in the arterial end of systemic capillary is 
only 95mmHg. The average oxygen tension in the tissues is 40mmHg. It is 
because of continuous metabolic activity and constant utilization of oxygen. 
Thus a pressure gradient of about 55mmHg exists between capillary blood and 
the tissues so that oxygen can easily diffuse into the tissues. 
Diffusion of carbon dioxide from tissues into the blood: 
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Due to continuous metabolic activity, carbon dioxide is produced 
constantly in the cells of the tissues. So the partial pressure of the carbon 
dioxide is high in the cells and is about 46mmHg. The partial pressure of 
carbon dioxide in arterial blood is 40mmHg. The pressure gradient of 6mmHg 
is responsible for the diffusion of carbon dioxide from tissues into the blood. 
Regulation of Respiration 
       The pattern of respiration is regulated is regulated by two mechanisms: 
I. Nervous or neural mechanism 
II. Chemical mechanism 
 
 
 
I. Nervous mechanism 
The respiratory centres are classified into two groups 
I. Medullary centre which are made up of 
a) Dorsal respiratory group of neurons: 
                       Situated in nucleus of tractussolitarius which is present in the 
upper   
                        part of the medulla oblongata. 
                        Responsible for basic rhythm of respiration. 
b) Ventral respiratory group of neurons: 
Situated in nucleus ambiguous and nucleus retroambiguous 
which are present in the medulla oblongata 
These neurons inactive during quiet breathing and become active 
during forced breathing. During forced breathing, these neurons 
stimulate both inspiratory muscles and expiratory muscle.  
 
II. Pontine centres which are 
a) Pneumotaxic centre: 
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Situated in thedorsolateral pert of reticular formation in upper 
pons. 
The pneumotaxic centre increases the respiratory rate by reducing 
the duration of inspiration. 
b) Apneustic centre: 
Situated in the reticular formation of lower pons. 
This centre increase the depth of inspiration by acting directly on 
the dorsal group neurons.  
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Factors affecting Respiratory centres 
a) Impulses from Higher centres: 
Impulse from anterior cingulate gyrus, genu of corpus callosum, 
olfactory tubercle, and posterior orbital gyrus of cerebral cortex inhibit 
the respiration. 
 Impulses from motor area and Sylvian area of cerebral cortex 
cause forced breathing. 
b) Impulses from stretch receptors of lungs: 
Stretch receptors are the receptors which give response to stretch 
of the tissues. These receptors are situated on the walls of the bronchi 
and bronchioles. During inspiration the lungs expand. This causes 
stretching of lungs and the air passage. So the stretch receptors are 
stimulated. The impulses from stretch receptors are transmitted by vagal 
afferent fibres to the respiratory centres. The impulses actually inhibit 
the dorsal group of neurons and so inspiration stops and expiration 
starts. Thus the over stretching of the lung tissues is prevented.  
c) Impulses from ‘J’ receptors of lungs: 
‘J’ receptors juxta capillary receptors which are present on the 
wall of the alveoli and have close contact with the pulmonary 
capillaries. Few cells are found on the wall of the bronchi. These 
receptors are the sensory nerve endings of vagus. 
The ‘J’ receptors are stimulated during the following conditions: 
 
• Pulmonary congestion 
• Pulmonary oedema 
• Pneumonia 
• Over inflation of lungs 
• Micro embolism in pulmonary capillaries 
• Exogenous and endogenous substances like  
• Histamine 
65 
   
• Halothane 
• Bradykinin 
• Serotonin 
• Phenyldiguanide 
These receptors are responsible for hyperventilation in the patients 
affected by pulmonary congestion and left heart failure. 
 
d) Impulses from Irritant receptors of lungs: 
These receptors present in the bronchi and bronchioles of lungs. 
The irritant receptors stimulated by irritant chemical agents such as 
ammonia and sulphur dioxide. These receptors send afferent impulses to 
respiratory centres via vagal nerve fibres.  
Stimulation of irritant receptors produces reflex hyperventilation along 
with bronchospasm, which prevents further entry of harmful agents into 
the alveoli. 
e) Impulses from Baroreceptors: 
Baroreceptors are situated in carotid sinus and arch of aorta, 
which give response to change in blood pressure. Whenever arterial 
blood pressure increases, baroreceptors are activated and send inhibitory 
impulses to medulla oblongata. This causes decrease in blood pressure, 
and inhibition of respiration.  
f) Impulses from Proprioceptors: 
Proprioceptors situated in joints, tendons and muscles, which 
give response to change in position of the body. The proprioceptors are 
stimulated during the muscular exercise and impulse to cerebral cortex, 
which in turn causes hyperventilation by sending impulses to the 
medullary respiratory centres. 
g) Impulses from Thermo receptors: 
Thermoreceptors are the cutaneous receptors, which give 
response to change in the environmental temperature. There are two 
types of thermo receptors namely,receptors for cold and receptors for 
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warmth. When the body is exposed to cold, the cold receptors are 
stimulated and send impulses to cerebral cortex which in turn stimulates 
the respiratory centres and causes hyperventilation. 
 
h) Impulses from Pain receptors: 
The pain receptors are those which give response to pain 
stimulus. Whenever pain receptors are stimulated, the impulses are sent 
to the cerebral cortex, which in turn stimulates the respiratory centres 
and causes hyperventilation.  
II Chemical mechanism 
       The chemical mechanism of regulation of respiration is operated 
through chemoreceptors. Chemoreceptors are stimulated by the changes in the 
chemical constituents of the blood such as, 
1. Hypoxia 
2. Hypercapnea 
3. Increased hydrogen ion concentration 
Chemoreceptors are classified into two types namely, 
I. Central chemoreceptors: 
Situated in the deeper part of the medulla oblongata, close to dorsal 
group of neurons.The hydrogen ions from carbon dioxide stimulate the 
central chemoreceptors. These stimulatory impulses are sent to dorsal 
respiratory group of neurons causing increased ventilation. 
II. Peripheral chemoreceptors: 
Situated in the carotid and aortic region. Reduction in partial pressure of 
oxygen is the most potent stimulant for the peripheral chemoreceptors. 
Whenever, the partial pressure oxygen decreases, the chemoreceptors 
are stimulated and send impulses through aortic and Hering’s  nerves. 
These impulses stimulate the dorsal group of neurons and send 
stimulatory impulses to respiratory muscles resulting in increased 
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ventilation. This provides enough oxygen and rectifies the lack of 
oxygen.   
BRONCHIAL ASTHMA 
Definition: 
                   Asthma is an inflammatory disease of the small airways, 
characterised by episodic, reversible bronchial obstruction due to hyper-
responsiveness of trachea bronchial tree to a multiplicity of intrinsic and 
extrinsic stimuli manifested clinically by paroxysms of polyphonic wheeze, 
dyspnoea, and cough which may be relieved spontaneously or as a result of 
therapy. 
Types: 
Extrinsic Asthma (Atopic asthma, early onset Asthma) 
Onset is in childhood. It occurs in atopic individuals who really form 
IgE antibodies in response to allergens. Atopic patients can be identified by 
skin sensitivity tests. Asthmatic inflammatory reaction is characterised by a 
cellular infiltrate rich in eosinophils. 
Intrinsic Asthma (Non-atopic Asthma, Late onset Asthma) 
It can begin at any age, especially in late adulthood. There is no role for 
allergens in the production of the disease. 
Factors precipitating Asthma 
• Cold air 
• Tobacco smoke 
• Dust, acrid fumes 
• Emotional stress 
• Respiratory infections (viral, bacterial) 
• Exercise 
• Drugs 
i  NSAIDs especially aspirin 
ii β- Blockers 
• Chemicals 
Sulfiting agents like Na or K bisulfite, Sulphur dioxide etc. 
 
• Allergens 
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a) Ingested (fish, nuts, strawberries) 
b) Inhaled (dust, pollen, house dust mite) 
c) Food additives (tartrazine, metabisulfite preservatives, monosodium 
glutamate or ajinomoto) 
d) Occupational allergens (grain-dust, wood-dust) 
Pathophysiology 
• Chronic airway inflammation as evidenced by cellular infiltration of 
airways by activated eosinophils, mast cells, macrophages, and T-
lymphocytes 
• Released mediators from the above cells cause bronchial smooth muscle 
contraction 
• Denudation and desquamation of the epithelium forming mucous plugs 
that obstruct the airway  
• Airway remodelling as evidenced by 
a) Smooth muscle hypertrophy and hyperplasia 
b) Goblet cell and sub-mucosal gland hypertrophy leading to mucous 
hypersecretion 
c) Collagen deposition causing thickening of lamina reticularis 
d) Cellular infiltration, oedema and possible airway wall thickening. 
Epidemiology 
The prevalence of asthma increased steadily over the later part of the 
last century in countries with a western lifestyle and is also increasing in 
developing countries. Current estimates suggest that 300 million people world-
wide suffer from asthma and an additional 100 million may be diagnosed with 
asthma by 2025. In childhood, asthma is more common in boys, but following 
puberty females are more frequently affected. The socio-economic impact of 
asthma is enormous, particularly when poor control leads to days lost from 
school or work, hospital admissions and for some patients, a premature death. 
Clinical Features 
• Wheezing 
Widespread, polyphonic, high pitched wheezes are heared. 
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Expiratory wheeze is heard with mild broncho-constriction. 
Inspiratory and expiratory wheezes are heard inmoderatebroncho-
constriction 
Inspiratory wheeze is heard in severe broncho-constriction. 
In near fatal asthma, the chest is silent. 
• Chest tightness 
• Breathlessness and 
• Cough with mucoid tenacious sputum 
Classification of severity 
 Symptoms Night-time 
symptoms 
PEF 
 
Step1 
Intermittent 
<1 time a week 
Asymptomatic and 
normal PEF between 
attacks 
≤ 2 times a 
month 
≥ 80% predicted 
Variability<20% 
Step2 
Mild persistent 
≥1 time a week but 
<1time a day 
>2 times a 
month 
≥ 80% predicted 
Variability<20-
30% 
Step3 
Moderate 
persistent 
Daily use β2 agonist 
daily attacks affect 
activity 
>1 time a 
week 
<80% Predicted 
Variability >30% 
Step4 
Severe Persistent 
Continuous limited 
physical activity 
Frequent ≤ 60% Predicted 
Variablity>30% 
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Diagnosis and Investigations 
Initial diagnosis of Bronchial asthma is based on observing the patients 
symptoms and health history. 
• Auscultate for specific sounds that indicate lung inflammation, such as 
moist rales,  crackling and wheezing that indicates airway narrowing. 
• A sputum culture may be performed particularly if the sputum is green 
or has blood on it to determine whether a bacterial infection is present. 
In diagnosing a chronic Lung disorder, a sample of sputum is collected 
using a procedure called bronchoscopy.  
• Chest x-ray:  
Chest x-ray should be taken to rule out other causes of wheezing  and 
also to rule out the presence of pneumothorax in all cases of severe 
acute asthma. 
• Pulmonary Function Tests: 
         PET shows obstructive type of lung disease. 
FEV1 following 2 puffs of beta agonist shows an increase by 15% or 
greater than the previous level. 
• Peak Expiratory Flow: 
      Serial recordings of PEF may show overnight fall (morning dip) and 
subsequent rise during the day in patients with asthma. 
      There are increased eosinophils in sputum and blood. Serum IgE is 
elevated in atopic asthma. 
• ECG 
71 
   
 
PEAK EXPIRATORY FLOW RATE 
PEFR - peak expiratory flow rate - The maximal airflow rate achieved while 
forcefully expelling air from the lungs, following maximal inspiration; 
expressed in litres/ min  Thus, peak expiratory flow is a measurement, which 
tells us whether bronchioles are in spasm and if yes, their severity. 
 
Significance of measuring PEFR 
 It is helpful in distinguishing between constrictive (TB, 
silicosis)andobstructive (asthma) lung disease. 
 In asymptomatic cases, it may be the only means of diagnosis        
 Can point out specific trigger factors for asthma. 
  Can help judge the response to medication.  
Normal values 
These depend on height, age and sex of an individual. Thus values are greater 
in tall people, adults and in men 
Using PEFR in day-to-day practice1. 
1.Every patient’s baseline PEFR must be noted. 
2. Judge how low is it as compared to expected value  
3. Look for improvement after nebulisation/ treatment. 
4. A reduction in more than 20% of a patient’s baseline value signifies severity. 
5. A PEFR of d signifies a critical stage. This patient must be hospitalized, 
otherwise he may go in respiratory failure. 
 
The PEFR of an individual should fall within a range of 20% on either side 
of his predicted normal value. 
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Expected PEFR in children 
Male/ Female child - 5 to 15 yrsHeight (Mts.) PEFR (lts/min) 
0.90 92 
0.95 108 
1.00 124 
1.05 147 
1.10 169 
1.15 192 
1.20 215 
1.25 238 
1.30 260 
1.35 283 
1.40 306 
1.45 329 
1.50 351 
1.55 374 
1.60 397 
1.65 420 
1.70 442 
1.75 465 
1.80 488 
Expected PEFR depending on height and age of a male 
73 
   
  
 
 
 
Male adult Ht (Age) 18/25 
yrs 
30 35 40 45 50 55 60 65 70 
1.55 Mt 515 
lts/min 
502 489 477 463 451 438 425 412 399 
1.60 534 520 508 495 482 469 456 443 430 417 
1.65 552 539 526 513 501 487 475 462 449 436 
1.70 570 558 544 532 519 506 493 480 467 454 
1.75 589 576 563 550 537 525 511 499 486 473 
1.80 607 694 582 568 556 543 530 517 504 491 
1.85 625 613 600 587 574 561 548 535 522 510 
1.90 644 631 618 606 592 580 567 554 541 528 
1.95 663 649 637 624 611 598 585 572 559 546 
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Expected PEFR depending on height and age of a female 
Female adult Ht (Age) 18/25 30 35 40 45 50 55 60 65 70 
1.45 367 358 349 340 331 322 313 304 295 286 
1.50 383 374 365 356 347 338 329 320 311 302 
1.55 400 391 382 373 364 355 346 337 328 319 
1.60 416 407 398 389 380 371 362 353 344 335 
1.65 433 424 415 406 397 388 379 370 361 352 
1.70 449 440 431 422 413 404 395 386 377 368 
1.75 466 457 448 439 430 421 412 403 394 385 
1.80 482 473 464 455 446 437 428 419 410 401 
75 
   
 
DIFFERENTIAL DIAGNOSIS 
1. Chronic bronchitis 
2. Emphysema 
3. Cystic fibrosis 
4. Viral bronchiolitis 
5. Mechanical airway obstruction 
6. Foreign body aspiration 
7. Endobronchial tumour 
8. Cardiac failure 
9. Superior vena cava syndrome 
10. Substernal thyroid 
11. Vocal card dysfunction 
12. Pulmonary embolism 
13. Pulmonary eosinophilia 
14. Drugs-ACEI,  β -blockers 
15. Systemic vasculitis 
16. Carcinoid syndrome 
17. Allergic bronchopulmonaryaspergillosis 
Management of Asthma 
Acute attack: 
 Get out of bed 
 Take extra puff of aerosol inhaler 
 Take some hot tea or beverage or sips of warm water 
 Injection of adrenaline 0.5ml subcutaneously 
 If aerosol is ineffective, prolonged repeated attacks at night causes 
immobilization, then start course of Prednisolone 5mg tablet, 2 tablets 
tds. Then reduce dose gradually. 
 Asthaline inhalation-Take deep breath for 5-10 seconds. Two puffs to be 
inhaled at the interval of 5 minutes. Alternative is terbutaline inhalation. 
If no response 
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 Injection salbutamol 200mg/IM or 100mg/IV or 
 Injection terbutaline 0.25-0.5mg SC or IV over 10 minutes followed by 
maintenance dose of 12.5mg/minute. 
 Antibiotics if evidence of infection-fever, purulent sputum. 
 
Chronic asthma: 
 Avoid known allergens 
 Avoid smoking 
 Drugs 
 Preventives – Beclate inhalation, inhalation 3-4 times daily or 
Oral Prednisolone or Betamethasone at minimum effective dose 
 Sodium Cromoglycate inhalation by metered dose inhaler 2 puffs 4 
times daily.   
 Ketofen 1mg tab, 1-2 tablets with food. 
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LITERATURE REVIEW OF TRIAL DRUGS 
þÄ¢í¸õ: 
 
Chemical Name   : Red sulphide of mercury 
 
¾ý¨Á  :  ¦ÅôÀõ 
 
¦ºö¨¸: 
 ¯¼ü§ÈüÈ¢  (Nutrient) 
 
Ì½õ   (Properties)  : 
 
  
§À¾¢ÍÃï ºó¿¢ ¦ÀÕÅ¢Ã½ ¿£§Ã¡Î¾ 
¸¡¾¸Ê ¸¡ºíì ¸ÃôÀ¡ýÒñ-§¿¡¾ 
×ÕÅ¢Äí¸ ºí¸¾Á¡ äÚ¸ðÊ Ôõ§À¡íì 
ÌÕÅ¢Äí¸ ºí¸Áò¨¾ì ¦¸¡û  
-À¾¡÷ò¾ Ì½ º¢ó¾¡Á½¢ 
• ÍÃõ 
• ºó¿¢À¡¾õ 
• ¸ÃôÀ¡ý  
• ¸¡ºõ     
§À¡ýÈ À¢½¢¸û ¾£Õõ. 
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¦Åí¸¡Ãõ: 
 
Chemical Name   : Sodium Biborate  
 
Í¨Å  : þÉ¢ôÒ¼ý ÜÊÂ ÐÅ÷ôÒ 
 
¾ý¨Á  : ¦ÅôÀõ 
 
À¢¡¢×   : þÉ¢ôÒ 
 
 
¦ºö¨¸: 
 
• À¢ÃºÅ¸¡¡¢ 
• ¸ü¸¨Ãîº¢ 
• ÕÐ×ñ¼¡ì¸¢ - (Emmenagogue) 
 
Ì½õ   (Properties) : 
 
¦º¡È¢Ò¨¼ ¦Âñ ÌýÁ¿¨Á §º¡¡¢Â¡ºõ 
ÀÈ¢¸¢Ã½¢ ¸øæÉõ Àý§É¡ö - ¦¿È¢¨Âò 
¾¼í¸½í¸ Àí¸¢ÕÁ¢ º÷ôÀÅ¢¼ï ºó¿¢ 
Â¢¼í¸½í¸ Äì¸¢ü§À¡ ¦Áñ 
-À¾¡÷ò¾ Ì½ º¢ó¾¡Á½¢ 
• þÕÁø ,Á¡ó¾õ, §¾¡¼õ ¿£ìÌõ 
• ¸Àò¨¾Ôõ ¿£÷À¢½¢¨ÂÔõ ¿£ìÌõ 
80 
   
 
¦Åû¨ÇâñÎ:- 
 
Botanical Name  :  Allium sativum 
Family         :  Lilliaceae 
À.¯    : ÌÁ¢ú ¾ñÎ 
Í¨Å  : ¸¡÷ôÒ 
¾ý¨Á  : ¦ÅôÀõ 
À¢¡¢×   : ¸¡÷ôÒ 
 
¦ºö¨¸: 
 ¯ ÃÁ¡ì¸¢ (Tonic) 
 ¯ ¼ü§ÈüÈ¢ (Nutrient) 
 ¦ÅôÀÓñ¼¡ì¸¢  (Stimulant) 
 §¸¡¨ÆÂ¸üÈ¢  (Expectorent) 
 ÒØì¦¸¡øÄ¢ (Anthelmentic) 
 «¸ðÎÅ¡Â¸üÈ¢  (Carminative) 
 Àº¢¾£òàñÊ (Stomachic) 
 
Ì½õ   (Properties) : 
 
ºýÉ¢§Â¡Î Å¡¾ó¾¨Ä §¿¡× ¾¡ûÅÄ¢ 
ÁýÉ¢ÅÕ ¿£÷§¸¡¨Å Åýº£¾õ - «ýÉ§Á 
¯ûÙûÇ¢ ¸ñÀ¡ö ¯¨ÇãÄ §Ã¡¸Óõ §À¡õ 
¦ÅûÙûÇ¢¾ýÉ¡ø ¦ÅÕñÎ. 
 
-«¸ò¾¢Â÷ Ì½Å¡¸¼õ 
• Á¢Ì ¸Àõ 
• ¾¨Ä §¿¡× 
• ¿£÷§¸¡¨Å       §À¡ýÈ À¢½¢¸û ¾£Õõ. 
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MATERIALS AND METHODS 
PROTOCOL 
STUDY DESIGN: 
        The open clinical trial on SWASA KASAM was conducted at the OPD 
section of  POST GRADUATE, POTHU MARUTHUVAM 
DEPARTMENT attached to ARIGNAR ANNA HOSPITAL OF INDIAN 
MEDICINE, Chennai-106, during the period 2010- 2013. 
POPULATION AND SAMPLE: 
          The population consists of all patients satisfying the inclusion and 
exclusion criteria mentioned below. Sample consists of swasa kasam patients 
attending the OPD of Arignar Anna Hospital, Arumbakkam, Chennai-106. 
SAMPLE SIZE: 
        The trial size will be 40 patients. 
INCLUSION CRITERIA 
1. Age:  between 20 - 80 years. 
2. Willing to give specimen of blood for investigation when required. 
3. Willing to attend the OPD once in 7 days.  
4. With the symptoms of Dyspnoea, Cough with expectoration, 
Wheezing, Tightness of chest, Rhinitis, Sneezing, Head ache.                                 
 EXCLUSION CRITERIA: 
1. Congestive cardiac failure 
2. Pulmonary tuberculosis 
3. Chronic bronchitis 
4. Bronchiectasis 
5. Bronchogenic carcinoma 
6. Pregnancy 
WITHDRAWAL CRITERIA 
• Intolerance to the drug and development of adverse reactions during 
drug trial. 
• Patient turned unwilling to continue in the course of clinical trial. 
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EVALUATION OF CLINICAL PARAMETERS: 
Patients are clinically evaluated by following parameters. 
HISTORY TAKING: 
      Age, Occupation, Socio economic status, Complaints and duration,Previous 
illness, Family history, Personal habits were recorder in the case sheet for every 
patient at the time of first visit to the OP. 
INVESTIGATIONS 
Blood: 
 TC              
 DC 
 ESR 
 Hb 
 Blood Sugar (F) & (PP) 
 Blood Urea 
 Serum Cholesterol 
 VDRL 
Urine   : 
 Albumin 
 Sugar 
 Deposits 
 Sputum for AFB 
 X-ray Chest PA View 
 PEFR (peak expiratory flow rate) 
  
CLINICAL DIAGNOSIS BASED ON SIDDHA SYSTEM 
      The parameters used to diagnose the disease swasa kasam based on siddha 
system are: 
 Poriaalaridhal 
85 
   
 Pulanaalaridhal 
 Vinaadhal 
 Uyirthathukkal 
 Udalthathukkal 
 Envagaithervu: 
Naa, Niram, Mozhi, Vizhi, Sparisam, Malam, Moothiram, Naadi. 
• Neerkuri: 
Niram, Manam, Nurai, Enjal, Edai. 
• Neikuri:  
 
 
TRIAL MEDICINE, DOSAGE, AND DURATION: 
 INTERNAL MEDICINES: 
I.  Linga mathirai 130mg 
Ingredients: 
 Purified lingam   - 100 gm 
 Purified vengaram – 100 gm 
 Garlic juice 
Procedure: 
 Purified lingam is powdered finely and purified vengaram also 
powdered. 
 Add both lingam and vengaram powder in kalvam  
 add garlic and grind it to make a tablet form at the weighit of 130 mg 
(kundri eadai. ) 
Dosage                           :   1 tab Tds, After food 
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Adjuvant                         :   Water 
Duration                         :   48 days 
Indications                    :    Iraippu (Asthma), Irumal(cough), Flatulence.  
Reference                      :   kannusami paramparai vaithiyam pg no.164-165 
 
 
 
 
 
 
      
 
 
 
 
 
LINGA MATHIRAI 
87 
   
 
 
 
 
 
 
 
 
 
 
Results & Observations 
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RESULTS AND OBSERVATION 
 
           The study on Swasa kasam was carried out in 40 patients in the OP/IP 
Department Pothumaruthuvam,  Government  Siddha medical College, 
Chennai-106 attached to Arignar Anna Hospital during 2010-2013 were 
analysed. The observation were made and tabulated with following criteria. 
 Sex Distribution 
 Age Distribution 
 Socio-Economic status 
 Occupational Reference 
 Personal habits and Diet 
 Kaalam Distribution 
 Paruvakaalam 
 Thinai Reference 
 Duration of illness 
 Mukkutram 
 Ezhuudalkattugal Reference 
 EnvagaiThervugal Reference 
 Neikuri Reference 
 Clinical features  
 Clinical Prognosis 
 Gradation of Results 
 Peak Expiratory flow Rate 
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1. SEX DISTRIBUTION: 
 
S. No. Sex No. Of cases / 40 Percentage (%) 
1 Male 19 47.5% 
2 Female 21 52.5% 
 
 
  
 
 
 
Inference: 
             Out of 40 patients, 19 cases (47.5%) were male and 21 cases (52.5%) 
were female. 
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2. AGE DISTRIBUTION: 
 
S. No Age groups No. Of cases/ 40 Percentage (%) 
1. Below 20 years 0 0% 
2. 21- 30 years 1 2.5% 
3. 31- 40 years 10 25% 
4. 41- 50 years 8 20% 
5. 51- 60 years 4 10% 
6. 61- 70 years 9 22.5% 
7. 71-80 years 8 20.5% 
 
 
Inference: 
        From selected 40 cases, 2 patients (5%) were below 20, 7 patients (17.5%) 
were between 21-30, 9 patients (22.5%) were between 31-40, 8 patients (20%) 
were between 31-40, 8 patients (20%) were between 41-50, 6 patients (15%) 
were between 61-70. 
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3. SOCIO-ECONOMIC STATUS: 
 
S. No Socio-economic 
status/Year 
No. Of cases Percentage (%) 
1. Poor ( below 10,000) 28 70% 
2. Middle class (10,000- 
20,000) 
9 22.5% 
3. High status ( Above 20,000) 3 7.5% 
 
 
 
 
Inference: 
         Regarding socio-economic status 28 patients (70%) comes under poor 
category, 9 patients (22.5%) comes under middle class category, and 3 patients 
(7.5%) comes under high class category. 
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4. OCCUPATIONAL REFERENCE:  
S. No Occupation No. Of cases Percentage 
1. Industry 9 22.5% 
2. Watch man 2 5% 
3. House wife 21 52.5% 
4. Others 8 20% 
 
 
 
 
 
 
Inference: 
    Out of 40 patients, 9 patients (22.5%) were industry, 2 patients (5%) were 
watch man, 21 patients (52.5%) were house wife, 8 patients (20%) were in 
other occupation. 
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5. PERSONAL HABITS AND DIET REFERENCE: 
S. No Personal habits & diet No. Of cases Percentage (%) 
1. Smoking 11 27.5% 
2. Alcoholic 3 7.5% 
3. Betalnut  & Tobacco chewing 5 12.5% 
4. Snuff 2 5% 
5. Vegetarian diet 9 22.5% 
6. Mixed diet include non 
vegetarian. 
31 77.5% 
 
 
Inference: 
       Regarding personal habits, 11 patients (27.5%) were smoker, 3 patients 
(7.5%) were Alcoholic, 5 patients (12.5%) were betalnut & Tobacco chewer, 
and 2 patients (5%) were snuff users. Regarding diet 9 patients (22.5%) takes 
vegetarian diet and 37 patients (77.5%) takes mixed diet.  
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6. KAALAM DISTRIBUTION: 
 
S. No Kaalam 
No. Of 
cases/40 
Percentage (%) 
1. Vali kaalam (0-33 yrs) 3 7.5% 
2. Azhal kaalam (33-66 yrs) 21 52.5% 
3. Iyya kaalam (66-100 yrs) 16 40% 
 
 
 
 
Inference: 
         Out of 40 patients, 3 patients (7.5%) comes under Vali kaalam, 21 
patients (52.5%) comes under Azhal kaalam, and 16 patient (40%) comes 
under Iyya kaalam. 
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7. PARUVAKAALAM: 
S. 
No 
Paruvakaalam 
Seasons 
Months 
No. Of 
cases/ 40 
Percentage 
(%) 
1. Kaarkaalam 
Avani, Puratasi, 
Mid Aug-Mid Oct 
15 37.5 
2. Koothirkaalam 
Iyppasi, 
Kaarthigai 
Mid Oct-Mid Dec 
7 17.5 
3. Munpani 
Margazhi, Thai 
Mid Dec-Mid Feb 
8 20% 
4. Pinpani 
Maasi, Panguni 
Mid Feb-Mid 
April 
- - 
5. Elavenil 
Chithirai, vaigasi 
Mid April- Mid 
June 
2 5% 
6. Mudhuvenil 
Aani, Aadi 
Mid June-Mid 
Aug 
8 20% 
         
I
nference:    
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 From selected 40 patients, 15 patients (37.5%) comes under Kaarkaalam, 7 
patients (20%) comes under Koothirkaalam, 8 patient (20%) comes under Munpani, 2 
Patient (5%) comes under Elavenil, 8 patients (20%) comes under Mudhuvenil 
kaalam. 
97 
   
 
8. THINAI REFERENCE: 
S. No Thinai No. Of cases/ 40 Percentage (%) 
1. Kurinji (Hill) 2 5% 
2. Mullai (Forest) 0 0 
3. Marudham (Fertile) 9 22.5% 
4. Neidhal (Sea) 29 72.5% 
5. Paalai (Desert) 0 0 
 
 
     Inference: 
       Out of 40 patients, 2 patient (5%) comes under kurinji,  patient (22.5%) 
comes under marudham, 29 patient (72.5%) comes under Neithal category. 
 
 
98 
   
9. DURATION OF ILLNESS: 
S. No Duration of illness No. Of cases/ 40 Percentage (%) 
1. Up to one month 11 27.5% 
2. 2-3 months 4 10% 
3. 3 months to one year 10 25% 
4. More than one year 15 37.5% 
 
 
 
Inference: 
       Out of 40 patients, 12 patients (30%) belongs to Up to one month category, 
and 6 patients (15%) belongs to 2-3 months category, 12 patients (30%) 
belongs to 3 months to one year category, 10 patients (25%) belongs to more 
than one year category. 
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10.  REFERENCE TO MUKKUTRAM 
I. VALI 
S. No Classification of vali No. Of cases Percentage (%) 
1. Pranan 40 100% 
2. Abanan 20 50% 
3. Viyanan 40 100% 
4. Udhanan 40 100% 
5. Samanan 16 40% 
6. Naagan 0 0% 
7. Koorman 6 15% 
8. Kirugaran 16 40% 
9. Devathathan 18 45% 
10. Dhananjayan 0 0% 
   
     
 
Inference:  From the selected 40 patients, pranan was affected in 40 patients 
(100%), Abanan in 20 patients (50%), Viyanan was affected in 40 patients 
(100%), Udhanan in 40 patients (100%), samanan in 16 patients (40%), 
Koorman in 6 patients (15%), Kirugaran in 16 patients (40%), Devathathan in 
18 patients (45%). 
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II.AZHAL 
S. No Classification of azhal No. Of cases Percentage (%) 
1. Analagam 16 40% 
2. Ranjagam 10 25% 
3. Saathagam 40 100% 
4. Aalosagam 6 15% 
5. Prasagam 0 0% 
 
 
 
Inference: 
         Out of 40 patients Analagam was affected in 16 patients (40%), 
Ranjagam was affected in 5 patients (25%), Sathagam was affected in 40 
patients (100%), Aalosagam was affected in 6 patients (15%). 
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III.  IYYAM 
S. No Classification of Iyyam No. Of cases Percentage (%) 
1. Avalambagam 40 100% 
2. Klethagam 16 40% 
3. Pothagam 0 0% 
4. Tharpagam 0 0% 
5. Santhigam 12 30% 
 
 
Inference: 
      Out of 40 patients, Avalambagam was affected in 40 patients (100%), 
Kiledhagam was affected in 16 patients (40%), Santhigam was affected in 
12 patients (30%). 
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11. EZHU UDALKATTUGAL  
S. No Ezhu udal kattugal No. Of cases Percentage (%) 
1. Saaram, 40 100% 
2. Senneer 10 25% 
3. Oon 0 0% 
4. Kozhuppu 0 0% 
5. Enbu 12 30% 
6. Moolai 0 0% 
7. Sukkilam/Suronitham 0 0% 
 
 
Inference: 
Out of 40 cases, Saaram was affected in 40 patients (100%), Senneer 
was affected in 10 patients (25%), Enbu was affected in 12 patients (30%).  
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12. ENVAGAI THERVUGAL REFERENCE 
S. No Envagai Thervugal No. Of cases Percentage (%) 
1. Naa 10 25% 
2. Niram 10 25% 
3. Mozhi 40 100% 
4. Vizhi            6 15% 
5. Sparisam 0 0% 
6. Malam 20 50% 
7. Moothiram 0 0% 
 
 
Inference: 
         Regarding Envagai thervu, Naa (coated) was affected in 10 patients 
(25%), Niram was affected in 10 patients (25%), Mozhi was affected in 40 
patients (100%), Vizhi was affected in 6 patients (15%), and Malam was 
affected in 20 patients (50%). 
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8.NAADI 
 
S. No Naadi No. Of cases Percentage (%) 
1. Vali Iyyam 20 50% 
2. Azhal Iyyam 20 50% 
 
 
   
 
 
Inference: 
        20 patients had Vali iyya naadi and 20 patients had Azhal iyya Naadi. 
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13. NEIKURI REFERENCE 
 
S. No Neikuri Character of 
urine 
No. Of 
cases 
Percentage 
(%) 
1. Vatha neer Spreads like snake 20 50% 
2. Pitha neer Spreads like ring 4 10% 
3. Kabha neer Float like pearl 16 40% 
 
 
 
 
Inference: 
           20  patients (50%) had vatha neer, 4 patients (10%) had Pitha neer, 16 
patients (40%) had Kabha neer.  
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14. CLINICAL FEATURES 
S. No Signs& Symptoms No. of cases Percentage (%) 
1. Dyspnoea 40 100% 
2. Cough with expectoration 40 100% 
3. Wheezing 40 100% 
4. Tightness of chest 40 100% 
5. Rhinitis 16 40% 
6. Sneezing 20 50% 
7. Head ache 10 25% 
8. Fever 0 0% 
9. Cyanosis 0 0% 
10. Clubbing 0 0% 
11. Loss of weight 0 0% 
Inference:  
Out of 40 patients, 40 patients (100%) had Dyspnoea, 40 patients (100%) had 
Cough with expectoration,40 patients (100%) had Wheezing, 40 patients 
(100%) had Tightness of chest, 16 patients (40%) had Rhinitis, 20 patients 
(50%) had Sneezing, 10 patients (25%) had Head ache. 
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15. CLINICAL PROGNOSIS 
S. No Signs&Symptoms Before Treatment After Treatment 
No. of 
cases 
Percentage 
(%) 
No. of 
cases 
Percentage 
(%) 
1. Dyspnoea 40 100% 2 5% 
2. Cough with Expectoration 40 100% 2 5% 
3. Wheezing 40 100% 2 5% 
4. Tightness of chest 40 100% 0 0 
5. Rhinitis 16 40% 2 5% 
6. Sneezing 20 50% 1 2.5% 
7. Head ache 10 50% 2 5% 
 
Inference: 
      After trearment Dyspnoea present in 2 patients (5%), Cough with 
expectoration present in 1 patients(2.5%),Wheezing present in 2 patient (5%), 
Rhinitis present in 2 patients(5%), Sneezing present in 1 patient (2.5%), Head 
ache present in 2 patient (5%) 
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16. GRADING OF RESULTS 
 
S. No Grading of results No. Of cases Percentage (%) 
1. Good 28 70% 
2. Moderate 10 25% 
3. Poor 2 5% 
 
 
 
 
Inference: 
       Out of 40 patients, 28 cases (70%) shows good result, 10 cases (25%) 
shows moderate result, 2 cases (5%) shows poor result.  
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PEAK EXPIRATORY FLOW RATE 
 
S. 
no 
NAME BeforeTreatment 
L/mnt 
AfterTreatment 
L/mnt 
1. Munusamy 120 240 
2. Kumaresan 200 310 
3. Bama 210 330 
4. Durgadevi 200 320 
5. Jaganathan 190 300 
6. Padmavathy 140 280 
7. Bharathy 170 290 
8. Saraswathy 110 200 
9. Thilaga 130 210 
10. Vijayakumar 120 240 
11. Vaiyapuri 140 270 
12. Murugesan 100 210 
13. Rani 110 240 
14. Guna 150 230 
15. Saravana 
bavanantham 
130 260 
16. Shanbegam 170 240 
17. Kumar 120 200 
18. Suganya 120 250 
19. Nanthagopal 150 260 
20. Narayanan 170 220 
21. Vani 140 270 
22. Adilakshmi 170 290 
23. Rupchand 110 200 
24. Lalitha 130 210 
25. Vedavalli 150 290 
26. Neelagandan 160 200 
27. Subramani 200 410 
28. Nagavalli 150 240 
29. Pakiri samy 190 230 
30. Yamuna 200 270 
31. Sengani 290 310 
32. Mary finoth 100 210 
33. Chandrasekar 120 250 
34. Sowndarjan 180 310 
35. Kathavarayan 200 330 
36. Manimuthu 150 290 
37. Amutha 190 310 
38. Usha 120 240 
39. Jaya pandian 140 270 
40. Parvatham 120 250 
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PEFR Prognosis Range: 
Grading of  Results:  
S. no PEFR  Prognosis Range No. Of patients Percentage % 
1. Above 100 27 67.5% 
2. 100 – 50 10 25% 
3. Below 50 3 7.5% 
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LABORATORY INVESTIGATION REPORT (OP) 
 
TC – Total Count        Hb – Haemoglobin       OEC – Occasional Epithelial Cells 
Dc – Differential Count               ESR – Erythrocyte Sedimentation Rate     OPC – Occasional Pus Cells 
P – Polymorph        Alb – Albumin       FPC – Few Pus Cells 
L – Lymphocyte        Sug – Sugar        FEC – Few Epithelial Cells 
  E – Eosinophil        Dep – Deposits 
 
 
SL. 
NO. 
OP. NO.              
 
NAME 
 
AGE/Sex 
 
HEAMOTOLOGICAL REPORT 
URINE ANALYSIS STOOL  EXAMINATION 
BEFORE TREATMENT AFTER TREATMENT ESR(mm) HB(Gm) 
TC 
(Cu/mm) 
DC 
TC 
(Cu/mm) 
DC BT AT 
BT AT 
BT AT BT AT 
P L E P L E ½ Hr 1 Hr ½ Hr 1 Hr Alb Sug Dep Alb Sug Dep Ova Cyst Ova Cyst 
1. 69 Munusamy 38/M 9600 55 39 6 9,800 56 38 6 2 4 2 4 15 13 Nil Nil OEC Nil Nil Nil Nil Nil Nil Nil 
2. 688 Kumaresan 41/M 9700 58 35 7 10,400 58 39 3 5 8 6 12 13 14.5 Nil Nil OEC Nil Nil OPC Nil Nil Nil Nil 
3. 545 Bama 63/F 9000 57 38 5 11,000 59 37 4 8 11 6 12 12 12.5 Nil Nil OEC Nil Nil OPC Nil Nil Nil Nil 
4. 8221 Durgadevi 32/F 9400 55 36 9 9,700 58 36 6 9 11 8 16 12 12.5 Nil Nil FEC Nil Nil Nil Nil Nil Nil Nil 
5. 9800 Jaganathan 55/M 9600 60 37 3    11,300 55 35 6 8 16 4 8 12.6 12 Nil Nil FEC Nil Nil Nil Nil Nil Nil Nil 
6. 9507 Padmavathy 62/F 9000 56 40 4 11,600 56 35 4 53 80 10 14 12.4 12.5 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
7. 8463 Bharathy 42/F 9400 55 39 6 10,100 62 34 4 32 54 4 10 12 12.8 Nil Nil FPC Nil Nil Nil Nil Nil Nil Nil 
8. 6792 Saraswathy 40/F 8700 54 39 7 10,000 62 28 4 20 41 6 10 9.4 13 Nil Nil FEC Nil Nil OPC Nil Nil Nil Nil 
9. 806 Thilaga 34/F 9200 53 40 7 9,500 58 30 3 20 45 3 6 12.6 15 Nil Nil FEC Nil Nil Nil Nil Nil Nil Nil 
10. 6184 Vijayakumar 78/M 8000 56 38 6 9,800 55 35 6 7 20 8 16 12.8 13.7 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
11. 6537 Vaiyapuri 65/M 9400 55 39 6 10,000 56 35 4 7 18 4 8 14 15 Nil Nil FPC Nil Nil Nil Nil Nil Nil Nil 
12. 6907 Murugesan 38/M 10300 60 27 13 10,100 58 34 5 9 11 10 14 12 14.6 Nil Nil FPC Nil Nil Nil Nil Nil Nil Nil 
13. 5918 Rani 46/F 10000 57 33 10 9,800 65 40 6 12 40 4 10 10.8 12 Nil Nil OEC Nil Nil Nil Nil Nil Nil Nil 
14. 631 Guna 48/F 9600 57 39 4 10,400 55 32 5 24 60 6 10 8 12.8 Nil Nil FEC Nil Nil Nil Nil Nil Nil Nil 
15. 7991 
Saravana 
bavanantham 
63/M 9700 
60 36 9 
9,600 59 35 6 2 7 3 6 13.8 14.2 
Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
16. 6318 Shanbegam 40/F 9700 58 39 3 9,900 60 37 4 30 64 4 10 10.8 13 Nil Nil FPC Nil Nil Nil Nil Nil Nil Nil 
17. 6230 Kumar 43/M 9600 57 39 4 9,700 55 32 5 8 20 6 10 13 12.8 Nil Nil Nil Nil Nil OPC Nil Nil Nil Nil 
18. 5999 Suganya 34/F 9700 58 36 6 9,800 57 28 3 30 56 3 6 10.4 12.5 Nil Nil FEC Nil Nil OPC Nil Nil Nil Nil 
19. 492 Nanthagopal 21/M 8600 52 39 4 9,700 58 35 7 11 20 9 18 12 14.1 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
20. 9011 Narayanan 74/M 9100 58 34 8 11000 58 37 2 15 34 3 6 10.4 13 Nil Nil FEC Nil Nil FPC Nil Nil Nil Nil 
99 
 
 
LABORATORY INVESTIGATION REPORT (IP) 
 
 
 
TC – Total Count        Hb – Haemoglobin       OEC – Occasional Epithelial Cells 
Dc – Differential Count               ESR – Erythrocyte Sedimentation Rate     OPC – Occasional Pus Cells 
P – Polymorph        Alb – Albumin       FPC – Few Pus Cells 
L – Lymphocyte        Sug – Sugar        FEC – Few Epithelial Cells 
  E – Eosinophil        Dep – Deposits 
 
SL. 
NO. 
IP. NO.              
 
NAME 
 
AGE/Sex 
 
HEAMOTOLOGICAL REPORT 
URINE ANALYSIS STOOL  EXAMINATION 
BEFORE TREATMENT AFTER TREATMENT ESR(mm) HB(Gm) 
TC 
(Cu/mm) 
DC 
TC 
(Cu/mm) 
DC BT AT 
BT AT 
BT AT BT AT 
P L E P L E ½ Hr 1 Hr ½ Hr 1 Hr Alb Sug Dep Alb Sug Dep Ova Cyst Ova Cyst 
1. 831/5346 Vani 35/F    11,300 55 35 6 9,700 55 32 5 9 11 8 16 13.2 13 Nil Nil FPC Nil Nil Nil Nil Nil Nil Nil 
2. 772/4366 Adilakshmi 58/F 11,600 56 35 4 9,800 57 28 3 8 16 4 8 15 14.5 Nil Nil FEC Nil Nil OPC Nil Nil Nil Nil 
3. 261/7848 Rupchand 67/M 10,100 62 34 4 9,700 58 35 7 53 80 10 14 12.2 12.5 Nil Nil FEC Nil Nil OPC Nil Nil Nil Nil 
4. 483/875 Lalitha 58/F 9,600 59 35 6 10,600 60 36 3 32 54 4 10 12.4 12.5 Nil Nil OPC Nil Nil Nil Nil Nil Nil Nil 
5. 106/9955 Vedavalli 60/F 9,900 60 37 4 9,700 55 32 5 20 41 6 10 12 12 Nil Nil FPC Nil Nil Nil Nil Nil Nil Nil 
6. 133/1068 Neelagandan 48/M 9,700 55 32 5 11,400 60 35 3 20 45 3 6 13 12.5 Nil Nil OEC Nil Nil Nil Nil Nil Nil Nil 
7. 502/8528 Subramani 60/    11,300 55 35 6 10,100 62 34 4 7 20 8 16 13 12.8 Nil Nil FEC Nil Nil Nil Nil Nil Nil Nil 
8. 1190/108 Nagavalli 50/F 10,100 62 34 4    11,300 55 35 6 11 32 6 10 12 13 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
9. 527/6124 Pakiri samy 70/M 9,600 59 35 6 11,600 56 35 4 3 7 3 6 15 15 Nil Nil FPC Nil Nil Nil Nil Nil Nil Nil 
10. 1305/3643 Yamuna 64/F 9,900 60 37 4 10,100 62 34 4 10 20 9 18 13.8 13.7 Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
11. 835/6587 Sengani 64/M 9,700 55 32 5 9,600 59 35 6 2 4 3 6 14.8 15 Nil Nil FEC Nil Nil Nil Nil Nil Nil Nil 
12. 175/213 Mary finoth 74/F 9,800 57 28 3 9,900 60 37 4 6 10 5 12 14.6 14.6 Nil Nil OEC Nil Nil Nil Nil Nil Nil Nil 
13. 245/3242 Chandrasekar 32/M 9,700 58 35 7 9,700 55 32 5 11 20 7 12 11 12 Nil Nil OEC Nil Nil Nil Nil Nil Nil Nil 
14. 157/2465 Sowndarjan 32/M 10,600 60 36 3    11,300 55 35 6 15 25 10 13 13 12.8 Nil Nil FEC Nil Nil Nil Nil Nil Nil Nil 
15. 17/4741 Kathavarayan 70/M 9,800 60 34 8 10,700 55 36 3 15 30 12 18 14 14.2 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
16. 170/206 Manimuthu 70/M 11,000 58 40 4 11,000 55 42 3 5 22 4 10 12.8 13 Nil Nil FPC Nil Nil Nil Nil Nil Nil Nil 
17. 297/5513 Amutha 72/F 10,500 55 42 5 9,800 56 38 6 5 10 8 16 13 12.8 Nil Nil Nil Nil Nil OPC Nil Nil Nil Nil 
18. 27/3210 Usha 54/F 9,800 56 40 2 10,400 58 39 3 3 5 4 8 12.4 12.5 Nil Nil FEC Nil Nil OPC Nil Nil Nil Nil 
19. 203/9851 Jaya pandian 46/M 11,400 60 35 3 11,000 59 37 4 7 12 10 14 14 14.1 Nil Nil OPC Nil Nil OPC Nil Nil Nil Nil 
20. 239/1114 Parvatham 74/M 10,100 62 34 4 9,700 58 36 6 3 5 4 10 13 13 Nil Nil FEC Nil Nil FPC Nil Nil Nil Nil 
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DISCUSSION 
         Swasa kasam, a clinical entity described by Yugi munivar in his Yugi 
Vaidhya Chinthamani 800. The classical symptoms are Dyspnoea, Cough with 
expectoration, Tightness of chest, Rhinitis, Sneezing. These features can be 
well compared with Bronchial asthma. 
          20 patients were selected and admitted in the inpatient Department, 
Pothumaruthuvam,  Government  Siddha medical College, attached to Arignar 
Anna Hospital, Arumbakkam, Chennai -106.  
All necessary investigations were carried out to all patients and trial 
medicines were given.  Regular daily follow up were done. All the patients 
were strictly advised to attend the O.P after discharged from in patient ward.   
        Another 20 patient were treated in out patient department. All the 
patients were advised to follow diet restriction with Yogasanam and 
Pranayamam. 
Sex: 
          Out of 40 patients, 19 cases (47.5%) were male and 21 cases (52.5%) 
were female. 
Age:  
           From selected 40 cases, High incidence of cases was noted in age 
ranging of 31-40 during the study. This is because of the change in food habits, 
occupational, seasonal and environmental factors and also due to smoking etc.          
Socio-economic status: 
           Regarding socio-economic status 28 patients (70%) comes under poor 
category, 9 patients (22.5%) comes under middle class category, and 3 patients 
(7.5%) comes under high class category.  People living in poor socio-economic 
status were more affected due to poor hygiene, polluted environment and 
malnutrition diet. 
Occupation: 
          Out of 40 patients, 9 patients (22.5%) were industry, 2 patients (5%) were 
watch man, 21 patients (52.5%) were house wife, 8 patients (20%) were in other 
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occupation. They are more prone to occupational hazards like exposure to 
industrial fumes, smokes, chemicals, dust, polluted environment pollens etc., 
which enhance the severity of Swasa kasam. 
Personal Habits: 
         Regarding personal habits, 11 patients (27.5%) were smoker, 3 patients 
(7.5%) were Alcoholic, 5 patients (12.5%) were betalnut & Tobacco chewer, 
and 2 patients (5%) were snuff users 
Diet: 
        Regarding diet 9 patients (22.5%) takes vegetarian diet and 37 patients 
(77.5%) takes mixed diet. 
Kaalam: 
         Out of 40 patients, 3 patients (7.5%) comes under Vali kaalam, 21 
patients (52.5%) comes under Azhal kaalam, and 16 patient (40%) comes 
under Iyya kaalam. 
Paruva kaalam: 
         From selected 40 patients, 15 patients (37.5%) comes under Kaarkaalam, 7 
patients (20%) comes under Koothirkaalam, 8 patient (20%) comes under Munpani, 2 
Patient (5%) comes under Elavenil, 8 patients (20%) comes under Mudhuvenil 
kaalam 
Thinai: 
 Out of 40 patients, 2 patient (5%) comes under kurinji,  patient (22.5%) 
comes under marudham, 29 patient (72.5%) comes under Neithal category. 
Duration of illness: 
          Out of 40 patients, 12 patients (30%) belongs to Up to one month 
category, and 6 patients (15%) belongs to 2-3 months category, 12 patients 
(30%) belongs to 3 months to one year category, 10 patients (25%) belongs to 
more than one year category. 
OBSERVATION OF ALTERED MUKKUTRAM 
Vali: 
From the selected 40 patients, pranan was affected in 40 patients 
(100%), Abanan in 20 patients (50%), Viyanan was affected in 40 patients 
(100%), Udhanan in 40 patients (100%), samanan in 16 patients (40%), 
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Koorman in 6 patients (15%), Kirugaran in 16 patients (40%), Devathathan in 
18 patients (45%). 
Azhal: 
           Out of 40 patients Analagam was affected in 16 patients (40%), 
Ranjagam was affected in 5 patients (25%), Sathagam was affected in 40 
patients (100%), Aalosagam was affected in 6 patients (15%). 
Iyyam: 
         Out of 40 patients, Avalambagam was affected in 40 patients (100%), 
Kiledhagam was affected in 16 patients (40%), Santhigam was affected in 12 
patients (30%). 
Ezhu udalkattugal:  
               Out of 40 cases, Saaram was affected in 40 patients (100%), Senneer 
was affected in 10 patients (25%), Enbu was affected in 12 patients (30%).  
 
Envagai thervu: 
         Regarding Envagai thervu, Naa (coated) was affected in 10 patients 
(25%), Niram was affected in 10 patients (25%), Mozhi was affected in 40 
patients (100%), Vizhi was affected in 6 patients (15%), and Malam was 
affected in 20 patients (50%). 
 Naadi: 
20 patients had Vali iyya naadi and 20 patients had Azhal iyya Naadi. 
 Neikuri: 
In Neikuri, 20  patients (50%) had vatha neer, 4 patients (10%) had 
Pitha neer, 16 patients (40%) had Kabha neer. 
Signs & Symptoms: 
          Out of 40 patients, 40 patients (100%) had Dyspnoea, 40 patients (100%) 
had Cough with expectoration,40 patients (100%) had Wheezing, 40 patients 
(100%) had Tightness of chest, 16 patients (40%) had Rhinitis, 20 patients 
(50%) had Sneezing, 10 patients (25%) had Head ache. 
Peak expiratory flow rate: 
         Out of 40 patients, 27 patients (67.5%) shows good result and 10 patients 
(25%) shows moderate result, 3 patients (7.5%) shows poor result.  
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Episodes of Wheezing: 
        Out of 40 patients, Episodes of wheezing  reduced in 70% of patients.   
Investigation: 
            Investigations like TC, DC, ESR, Hb, Blood sugar, Serum Cholesterol, 
Blood urea were examined and urine analysis for albumin, sugar and deposits 
were taken. Sputam for AFB, X-Ray chest PA view and Peak expiratory flow 
rate were taken. 
Suvai-Mukkutra Theory: 
          Swasa kasam is caused by the derangement of Iyya kutram which 
accompany with Vali kutram. The five properties, Suvai (Taste), Gunam 
(Property), Veeriyam (Potency), Pirivu (class) and Mahimai (action) will bring 
all the kutrams and kattugal to its normal limit.  Linga mathirai has the 
following features of Suvai and Veeriyam. 
S. No Drug Suvai Veeriyam 
1. Lingam - Veppam 
2. Vengaram Inippu, Thuvarppu Veppam 
3. poondu Kaarpu Veppam 
 
The predominant veeriyam present in Linga maathirai is veppam. 
The predominant suvai present in Linga maathirai is kaarppu. 
Dose: 
    130 mg. 1 tablet, Tds , with water. 
              The deranged kutram in swasa kasam is kabam, the bootham is man + 
neer. The prepared trial drug has kaarppu suvai. The bootham is vali+ thee. So 
predominant suvai present in linga maathirai which brings the deranged iyya 
kutram is normal. Hence, the treatment is based on ETHIRURAI 
MARUTHUVAM. 
Clinical Study: 
          All the patients were treated with Linga mathirai for an average of 48 
days. Blood and urine were once again tested after the completion of treatment. 
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 Bio chemical analysis: 
The results of Bio-chemical analysis reveals that Naayuruvi kuzhi 
thylam contains, Acid radicals such as Sulphate and Phosphate. Basic 
radicals such as Calcium, Potassium, and Ammonoum. 
 Pharmacological study: 
  Pharmacological study reveals that Linga mathirai contains Anti-
histamine and Bronchodilator activity.  It was safe, well tolerated and did not 
produce any toxicity 
Bio statistical analysis:. 
            The p value is significant (<o.o1), The hypothesis is not accepted. So 
there is significant reduced symptoms among the patients for the treatment of 
Swasa kasam. Hence it is concluded that the treatment was effective and 
significant         
All the patients were advised to practice Pranayamam and Yogasanam.  
 Out of 40 patients 70% of cases shows good result, 25% of the cases shows 
moderate result and 5% of cases shows poor result. 
   From the above all clinical assessment and results show good and encourage. 
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SUMMARY 
           The clinical study on SWASA KAASAM was carried out in Post 
graduate department of Maruthuvam, Government Siddha Medical College, 
Arignar Anna Hospital, Chennai –106 during the period of 2011-2012. 
 A total of 40 patients were treated in the O.P and I.P department. The 
clinical and pathological assessment was carried out on the basis of both 
Siddha and modern aspects.   
 All the 40 patients were treated with Linga maathirai (1 tablet tds daily                            
with water). The duration of the treatment was fixed as 45 days.  The responses 
were assessed once in 7 days for all the patients. 
 The peak incidence of Swasa kasam was found to be in 31-40 years of 
age group of both sex. 
 The prevalence of the disease was high among lower class population 
70%, Middle class 22.5%, and High class population 7.5%. 
 Out of 40 patients, 22.5%were industry, 5% were watch man, 52.5% 
were house wife, 20% were other workers. 
 Among dietary patterns, 77.5% patients consume Mixed diet.  
 Regarding personal habits, 27.5% were smoker, 7.5% were Alcoholic, 
12.5% were betalnut & Tobacco chewer, and 5% were snuff users. 
 Out of 40 patients, 7.5% comes under Vali kaalam, 52.5% comes under 
Azhal kaalam, and 40% comes under Iyya kaalam. 
 From selected 40 patients, 37.5% comes under Kaarkaalam, 17.5% 
comes under Koothirkaalam, 20% comes under Munpani, 5% comes 
under Elavenil, 20% comes under Mudhuvenil kaalam 
 In vatham - Pranan, Udhanan and Vyanan (100%),Kirugaran (40%), 
Samanan(40%), Abanan (20%) Devadhathan (45%), Koorman 
(15%)were affected. 
 In pitham - Sadhaga Pitham (100%), Ranjaga pitham (25%), Aanalagam 
(37.5%), Aalosagam (15%) were affected. 
 In Kapham - Avalambagam (100%) and Kilethagam (40%), and 
Santhigam (30%) were affected. 
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 Among Ezhu Udal Kattugal, Saaram, (100%), Enbu (30%) and Seneer 
(25%) were affected. 
 Among Envagai Thervugal, Vizhi (15%), Niram (25%), Naa (25%), 
Mozhi (100%), and Malam (50%)  were affected. 
 Naadi in Swasa kasam patients felt as, Vali iyya naadi (50%) and  
Azhaliyyam naadi (50%). 
 The Neikuri examination 50% show Vatha neer, 10% Pitha neer, 40% 
shows Kabha neer.  
 Out of 40 patients, 28 patients (70%) shows good result and 10 patients 
(25%) shows moderate result, 2 cases (5%) shows poor result.  
 Regarding Peak expiratory flow rate, 67.5% shows good result and 25% 
shows moderate result,7.5% shows poor result.  
 The ingredients of trial medicines were found to have the properties of 
controlling Swasa kasam. 
 The clinical trial conducted in selected patients were satisfactory and 
encouraging. 
 The Pharmacological studies of the trail medicine shows good result. 
 The bio-statistical report of the clinical trial shows significant result P 
value <0.01. 
 Among 40 cases, 70% of the cases show good results and 25% of the 
cases show moderate result, 5% of the cases shows poor result. 
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CONCLUSION 
 Swasa kasam is primarily due to the derangement of Vali and Iyya 
kutram. 
 The trial medicines  Linga maathirai predominating kaarpu suvai 
neutralizes the deranged Iyya kutram. 
 Linga maathirai did not produce any toxicity in preclinical study. So it is 
a very safe drug for Swasa kasam. 
 From the preclinical pharmacological studies it is evident that the trial 
medicines have Anti histamine and Broncho dilator activity. 
 No contra indication was reported during the course of the treatment. 
 The trial medicines gave maximum relief from the symptoms of Swasa 
kasam. 
 The preparation of trial medicine is easy and economical. 
 Therefore I conclude the trial drug for disease swasa kaasam was 
statisfactory and encouraging. 
 
122 
   
 
 
 
 
 
 
 
Annexures 
 
 
 
 
 
 
 
 
 
123 
   
 
 
 
 
 
 
Certificates 
 
 
 
 
 
 
 
 
 
 
 
 
124 
   
 
 
 
 
 
 
 
Bio-chemical analysis 
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BIO-CHEMICAL ANALYSIS OF TRIAL MEDICINES 
 
Preparation of Sodium Carbonate extract: 
 2 gm of the sample drug  is mixed  5 gm of Sodium carbonate and taken 
in a 100 ml beaker and 20 ml of distilled water is added.  The solution is boiled 
for 10 minutes, cooled and then filtered.  The filtrate is called sodium carbonate 
extract. 
 
 
 
S.No. 
 
Experiment 
 
Observation  
 
Inference 
1 Test for Acid Radicals   
a. Test for Sulphate 
2 ml of the above prepared extract 
is taken in a test tube.  To this add 
2ml of 4% Ammonium oxalate 
solution. 
Absence of              
White  Precipitate 
 
Absent 
b. 2ml of extract is added with 2ml 
of dilute hydrochloric acid until 
the effervescence ceases off.  Then 
2ml barium chloride solution is 
added. 
Absence of              
White  Precipitate 
 
Absent 
2. Test for Chloride: 
2ml of extract is added with dilute 
nitric acid till the effervescence 
ceases.  Then 2ml of silver nitrate 
solution is added. 
 
white precipitate 
obtained 
 
Present 
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3. Test for Phosphate 
2ml of the extract is treated 
with 2 ml of Ammonium 
molybdate  solution and 2ml of 
concentrated nitric acid. 
Absence of 
Yellow Precipitate 
 
Absent 
4. Test for Carbonate: 
2ml of the extract is treated 
with 2ml of magnesium 
sulphate solution. 
Absence of white 
precipitate 
 
Absent 
5. Test for Sulphide: 
1 gm of the substance is treated 
with 2ml of concentrated 
Hydrochloric acid 
Absence of Rotten 
egg smelling 
 
Absent 
6. Test for Nitrate: 
1gm of the substance is heated 
with copper turnings and 
concentrated sulphuric acid 
and viewed the test tube 
vertically down. 
Absence of reddish 
brown gas. 
 
Absent 
7. 
a. 
Test for Fluoride and oxalate 
2ml of the extract is added with 
2ml of dilute acetic acid and 
2ml of calcium chloride 
solution and heated.  
Absence of white 
precipitate 
 
Absent 
b. 5 drops of clear solution is 
added with 2ml of dilute 
sulphuric acid and slightly 
warmed to this, 1 ml of dilute 
potassium permanganate 
solution is added.  
Absence of KMNO4 
solution 
discolourisation. 
Absent 
8. Test for Nitrite 
3 drops of the extract is placed 
on a filter paper.  On that, 2 
drops a Acetic Acid and 2 
drops of Benzidine solution is 
placed. 
 
Absence of 
yellowish red colour 
 
Absent 
9. Test for Borate 
2 pinches of the substance is 
made into paste by using 
Sulphuric acid and Alcohol 
(95%) and introduced into the 
blue flame. 
Absence of Green 
tinged flame 
 
Absent 
II. TEST FOR BASIC RADICALS  
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10. Test for lead 
2 ml of the extract is added 
with 2 ml of Potassium iodide 
solution 
Absence of Yellow 
precipitate 
 
Absent 
11a Test for Copper 
One pinch of substance is 
made into paste with 
concentrated Hydrochloric acid 
in a watch glass and introduced 
into the non luminous part of 
the flame. 
Absence of Bluish 
green coloured 
flame. 
 
Absent 
b. 2ml of the extract is added with 
excess of Ammonia solution 
Absence of deep 
blue Absent 
12. Test for Aluminium 
To the 2 ml of extract.  Sodium 
Hydroxide solution is added in 
drops to excess. 
Absence of   White 
precipitate. Absent 
13a Test for Iron 
To the 2 ml of extract, 2 ml of 
Ammonium Thiocyanate 
solution is added. 
Absence of Blood 
red colour Absent 
b. To the 2 ml of extract, 2 ml of 
Ammonium Thiocyanate 
solution and 2 ml of 
concentrated Nitric Acid is 
added. 
Absence of Blood 
red colour. Absent 
14. Test for Zinc 
To the 2 ml of extract Sodium 
Hydroxide solution is added in 
drops to excess. 
 White precipitate 
Obtained . Present 
 15. Test for Calcium 
2 ml of the extract is added 
with 2 ml of 4% Ammonium 
Oxalate solution. 
Absence of   White 
precipitate. Absent 
16. Test for Magnesium 
 2ml of extract, Sodium 
Hydroxide solution is added in 
drops to excess. 
Absence of   White 
precipitate. Absent 
17. Test for Ammonium 
 2 ml of extract few ml of 
Nessler’s Reagent and excess 
of Sodium Hydroxide solution 
are added. 
 
Absence of   
Reddish brown 
precipitate . 
 
Absent 
18. Test for Potassium 
A pinch of substance is treated 
Yellow precipitate 
Obtained. Present 
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with 2 ml of Sodium Nitrite 
solution and then treated with 2 
ml of Cobal Nitrate in 30% 
glacial Acetic acid. 
19. Test for Sodium 
2 pinches of the substance is 
made into paste by using 
Hydrochloric acid and 
introduced into the blue flame 
. 
Absence of Yellow 
colour flame Absent 
20. Test for Mercury 
2 ml of the extract is treated 
with 2 ml of Sodium 
Hydroxide solution. 
 
Absence of yellow 
precipitate Absent 
21. Test for Arsenic 
2 ml of extract is treated with 2 
ml of silver Nitrate solution 
Absence of                                                                                                                    
Yellow precipitate. Absent 
22. Test for Starch 
2ml of extract is treated with 
weak iodine solution 
Absence of                                                                                                                    
Bluecolour.. Absent 
23. Test of reducing Sugar 
5ml of Benedicts qualitative 
solution is taken in a test tube 
and allowed to boil for 2 
minutes and added  10 drops of 
the extract and again boiled for 
2 minutes.  The colour changes 
are noted. 
Green colour is 
obtained. Present 
24.  Test of  the alkaliods               
2ml of the extract is treated 
with  2ml of potassium lodide 
solution. 
Absence of                                                                                                                    
Red colour. Absent 
25. 
 
 
 
 
Test of  the proteins 
2ml of the extract is treated 
with  2ml of 5% NaOH ,mix 
well and add 2 drops of copper 
sulphate solution. 
Absence of                                                                                                                    
Violet  colour. Absent 
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RESULTS:   
The given sample contains. 
Drug  Name : Linga maathirai.  
1. Chloride 
2. Zinc 
3. Pottassium 
4. Reducing sugar 
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Toxicological  
study  
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ACUTE AND SUB ACUTE TOXICITY STUDY ON LINGATHI 
MATHIRAI  
 
Animals:  
 Mice of either sex weighing 25-30g and rats weighing 210-240g were 
obtained from the animal house of Vels University. The animals were used 
with the approval of the Institute animal ethics committee and obtained from 
Vels University, Chennai. They were fed with a balanced standard pellet diet 
and maintained under standard laboratory conditions, providing 24-280C 
temperature, standard light cycle (12 h light, 12 h dark) and water ad libitum. 
Animals were kept in cages with raised floors of wide mesh to prevent 
coprophagy. Animal welfare guidelines were observed during the maintenance 
period and experimentation. The rats were randomly assigned to control and 
different treatment groups, six animals per group. 
(XIII/VELS/PCOL/15/2000/CPCSEA/IAEC/08.08.2012). The animals were 
acclimatized for one week under laboratory conditions.  
 
ACUTE TOXICITY STUDY-OECD 425 GUIDELINES 
 Acute oral toxicity test for the Lingathi Mathirai was carried out as per 
OECD Guidelines 425. As with other sequential test designs, care was taken to 
ensure that animals are available in the appropriate size and age range for the 
entire study. The test substance is administered in a single dose by gavage 
using a stomach tube or a suitable intubation cannula. The fasted body weight 
of each animal is determined and the dose is calculated according to the body 
weight. After the substance has been administered, food was withheld for a 
further 2 hours in mice. The animals were observed continuously for the first 4 
h and then each hour for the next 24 h and at 6 hourly intervals for the 
following 48 h after administering of the test drug, to observe any death or 
changes in general behaviour and other physiological activities. Single animals 
are dosed in sequence usually at 48 h intervals. However, the time interval 
between dosing is determined by the onset, duration, and severity of toxic 
132 
   
signs. Treatment of an animal at the next dose was delayed until one is 
confident of survival of the previously dosed animal.  
Observation of toxicity signs: General behavior, respiratory pattern, 
cardiovascular signs, motor activities, reflexes, change in skin and fur, 
mortality and the body weight changes were monitored daily. The time of 
onset, intensity, and duration of these signs, if any, was recorded.  
SUB-ACUTE TOXICITY  
 In a 28-days sub acute toxicity study, twenty four either sex (3+3) rats 
were divided into four groups of 6 rats each. Group I that served as normal 
control was administered with distilled water (p.o.) while groups II, III and IV 
were administered daily with the Lingathi Mathirai (p.o.) for 28 days at a dose 
of 1.0, 2.0 and 4.0 g/kg respectively. The animals were then observed daily for 
gross behavioural changes and any other signs of subacute toxicity. The weight 
of each rat was recorded on day 0 and weekly throughout the course of the 
study, food and water consumption per rat was calculated. At the end of the 28 
days they were fasted overnight, each animal was anaesthetized with 
diethylether, following which they were then dissected and blood samples were 
obtained by cardiac puncture into heparinised tubes. The blood sample 
collected from each rat was centrifuged with 3000 X g at 4oC for 10 min to 
separate the serum and used for the biochemical assays.  
Hematological and blood biochemical analyses:  
 At the end of the study, all animals were kept fasted for 16-18 h and 
then anesthetized with anesthetic ether on the 28th day. Blood samples for 
hematological and blood chemical analyses were taken from retro orbital vein. 
Heparinized blood samples were taken for determining complete blood count 
(white blood cell count, differential white blood cell count, platelet count, red 
blood cell count, hematocrit, and hemoglobin) by semiautomated hematology 
analyzer. The serum from non-heparinized blood was carefully collected for 
blood chemistry and enzyme analysis (glucose, creatinine, total protein, 
albumin, total and direct bilirubins, serum glutamate-oxaloacetate transaminase 
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(SGOT), serum glutamate pyruvate transaminase (SGPT), and alkaline 
phosphatase (ALP)) were automatically determined using autoanalyzer. 
Necropsy:  
 All rats were sacrificed after the blood collection. The positions, shapes, 
sizes and colors of internal organs were evaluated. The Spleen, Testes, Pancrea, 
Lung, Liver, Brain, Heart, Stomach, Intestine, Bone, Ovary, and Kidney tissues 
were excised from all rats to visually detect gross lesions, and weighed to 
determine relative organs’ weights and preserved in 10% neutral formalin for 
histopathological assessment. The tissues were embedded in paraffin, and then 
sectioned, stained with haematoxylin and eosin and were examined 
microscopically. 
Statistical analysis 
 Values were represented as mean ± SEM. Data were analysed using 
one-way analysis of variance (ANOVA) and group means were compared 
using the Tukey-Kramer Multiple Comparison Test using GraphPad Instat-V3 
software. P values < 0.05 were considered significant. 
RESULTS 
1) All the animals from control and all the treated dose groups up to 400 mg/kg 
survived throughout the dosing period of 28 days. 
2) No signs of major or significant intoxication were observed in animals from 
lower to higher dose groups during the dosing period of 28 days. 
3) Animals from all the treated dose groups exhibited comparable body weight 
gain with that of controls throughout the dosing period of 28 days. 
4) Food consumption of control and treated animals was found to be 
comparable throughout the dosing period of 28days. 
5) Ophthalmoscopic examination, conducted prior to and at the end of dosing 
period on animals from control and all the treated dose groups did not reveal 
any abnormality. 
6) Haematological analysis conducted at the end of the dosing period on day 
28, revealed no significant abnormalities attributable to the treatment. 
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7) Biochemical analysis conducted at the end of the dosing period on day 28, 
revealed no remarkable abnormalities attributable to the treatment. 
8) Functional observation tests conducted at termination revealed no 
abnormalities. 
9) Urine analysis, conducted at the end of the dosing period in week 4 and at 
the end of recovery period in week 6, revealed no abnormality attributable to 
the treatment. 
10) Organ weight data of animals sacrificed at the end of the dosing period was 
found to be comparable with that of respective controls. 
11) Gross pathological examination did not reveal any abnormality. 
12) Histopathological examination did not reveal any abnormality. 
CONCLUSION: 
 Based on these findings, no toxic effect was observed upto 400mg/kg of 
Lingathi Mathirai over a period of 28 days. So, it can be concluded that the 
Lingathi Mathirai can be prescribed for therapeutic use in human with the 
dosage recommendations of upto 400mg/kg. body weight p.o. 
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Table 1: Dose finding experiment and its behavioral Signs of Toxicity 
No Dose mg/kg 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
1. 500 + - - + - + - - - - - - - - - - - - - - 
2 1000 + - - + - + - - - - - - - - - - - - - - 
3 2000 + - - + - + - - - - - - - - - - + - -  - 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Decreased Motor Activity 8. Tremors 9. Convulsions 10. Muscle 
Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. Diarrhoea 18. Writhing 19. Respiration 20. Mortality 
 
Table 2. Body wt (g) of albino rats exposed to Lingathi Mathirai for 28days. 
Dose 
(mg/kg/day) 
Days 
1 7 14 21 28 
Control 125.26±4.12 122.62±5.84 125.10±5.76 126.10±4.44 126.17±5.22 
100 124.21±4.18 125.30±4.91 126.20±5.11 131.46±7.15 132.45±6.62 
200 126.30±3.26 125.61±5.74 125.87±4.46 126.44±5.65 127.62±7.41 
400 130.11±5.70 134.11±5.62 136.42±4.34 135.19±5.75 136.15±8.74 
Values are mean ± S.E.M. (Dunnet’t' test). nsP > 0.05; Vs Control N=6. 
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Table 3. Food (g/day) intake of rats exposed to Lingathi Mathirai for 28days. 
Dose (mg/kg/day) Days (gms/rats) 
1 7 14 21 28 
Control 45.12±2.45 45.44±2.77 45.61±2.32 45.57±2.88 47.27±3.45 
100 42.34±2.58 45.71±2.60 45.70±2.74 47.61±2.74 48.15±3.42 
200 42.10±2.44 42.62±2.45 46.05±2.56 46.63±3.40 46.20±3.10 
400 44.55±2.62 45.35±2.71 47.30±2.14 48.77±2.55 48.15±3.00 
Values are mean ± S.E.M. (Dunnet’t' test). nsP > 0.05; Vs Control N=6. 
Table 4. Water (ml/day) intake of rats exposed to Lingathi Mathirai for 28days. 
 
Dose (mg/kg/day) 
Days(ml/rat) 
1 7 14 21 28 
Control 52.44±2.42 51.22±3.58 52.46±3.15 52.21±3.12 52.11±3.43 
100 51.50±2.15 51.1±3.12 51.00±3.16 52.14±3.15 54.25±2.14 
200 51.12±2.50 53.10±3.40 54.27±3.40 52.34±2.24 55.10±3.12 
400 50.43±3.44 52.22±3.10 50.12±3.02 51.25±3.10 55.16±3.10 
Values are mean ± S.E.M. (Dunnet’t' test). nsP > 0.05; Vs Control N=6. 
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Table 5. Hematological parameters after 28days treatment with Lingathi Mathirai in rats. 
Parameter Control 100 mg/kg 200 mg/kg 400 mg/kg 
RBC (millions/cu.mm) 5.12±0.30 5.14±0.30 5.33±0.32 5.79±0.31 
Hb (g/dl) 13.20±1.3 13.50±1.2 13.30±1.4 13.21±1.4 
PCV (%) 45.22±1.50 44.5±1.2 44.15±1.5 45.00±2.0 
WBC(cells/cu.mm) 7325±341 7275±320 7304±382 7328±420 
Neutrophil (%) 52.22±4.00 54.00 ±3.10 50.32±3.15 49.42±3.22 
Lymphocytes (%) 44.02±2.23 45.2±3.1 48.18±3.0 48.22±3.4 
Eosinophil’s (%) 6.20±0.41 5.62±0.57 5.92±0.48 5.62±0.44 
Monocytes (%) 4.2±0.2 3.3±0.2* 3.3±0.3* 3.5±0.2 
Basophils (%) 0±0 0±0 0±0 0±0 
Platelets (105 cells/cu.mm) 1.42±0.06 1.50±0.07 1.71±0.05** 1.45±0.04 
MCV(Fl) 78.5±2.0 81.4±1.3 81.3±2.0 82.5±2.2 
MCHC (pg) 25.1±1.0 24.22±1.7 25.1±1.2 26.52±1.6 
Values are mean of 6 animals ± S.E.M. (Dunnett's test). *P<0.05; **P<0.01. N=6. 
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Table 6. Effect of treatment with Lingathi Mathirai on biochemical (LFT, RFT, Lipid Profile) Parameters in rats. 
Values are mean of 6 animals ± S.E.M. (Dunnet's test). *P<0.05; **P<0.01. Vs Control  
       Parameter Control 100 mg/kg 200 mg/kg 400 mg/kg 
Glucose (mg/dL) 75.13±5.00 74.50±4.88 71.22±5.00 73.32±5.10 
Total Bilirubin (mg/dL) 0.203±0.05 0.204±0.05 0.204±0.05 0.202±0.04 
Bilirubin direct (mg/dL) 0.1±0.03 0.1±0.03 0.1±0.04 0.1±0.04 
Creatinine (mg/dL) 0.90±0.04 0.91±0.05 0.93±0.03 0.92±0.04 
BUN (mg/dL) 18.30±1.26 18.50±1.42 18.52±1.45 18.24±1.22 
AST (IU/L) 122.24±5.10 126.14±6.52 125.12±5.30 125.4±5.44 
ALT (IU/L) 34.14±3.32 32.28±2.57 34.45±2.15 35.90±2.24 
ALP (IU/L) 77.52±4.27 78.10±4.04 69.28±4.30 68.15±4.00 
Total cholestrol (mg/dL) 58.10±5.24 57.00±5.12 56.50±4.20 55.20±4.22 
Total protein (g/dL) 8.00±0.71 7.48±0.55 7.42±0.62 7.67±0.72 
Albumin (g/dL) 2.52±0.05 2.70±0.06* 2.70±0.04* 2.62±0.04 
Urea(mg/dL) 54.41±2.98 56.00±3.88 55.11±2.54 56.14±1.72 
Uric acid (mg/dL) 1.96±0.12 1.27±0.14** 1.30±0.13** 1.27±0.12** 
Na m.mol 144.62±5.10 142.2±5.00 144.23±4.50 142.20±4.78 
K m.mol 21.42±2.36 18.25±1.81 21.05±1.90 20.12±2.42** 
Cl m.mol 101.22±4.12 100.42±4.08 102.82±5.00 100.11±5.02 
HDL(mg/dL) 13.17±1.22 13.04±1.62 13.40±1.14 13.01±2.28 
LDL(mg/dL) 42.45±2.82 42.2±3.00 42.52±3.15 42.45±3.13 
VLDL(mg/dl) 16.40±2.02 16.17±2.41 16.30±1.70 15.41±1.50 
Triglycerides (mg/dl) 85.54±3.00 86.16±2.01 87.11±2.32 87.72±2.42 
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Table-7 Urine Analysis 
Parameters Control 100 mg/kg 200 mg/kg 400 mg/kg 
Colour Yellow Yellow Yellow Yellow 
Transparency Clear Slightly turbid Slightly cloudy Slightly turbid 
Specific gravity 1.010 1.010 1.010 1.010 
PH >7.2 >8.0 >8.0 >9.0 
Protein Nil 3+ 3+ 3+ 
Glucose Nil Nil Nil Nil 
Bilirubin -ve -ve -ve -ve 
Ketones -ve +ve +ve +ve 
Blood Absent Absent Absent Absent 
Urobilinogen Normal Abnormal Abnormal Abnormal 
Pus cells 0-cells/HPF 1-cell/HPF 2-cells/HPF 1-cell/HPF 
RBCs Nil Nil 0-1cells/HPF Nil 
Epithelial cells Nil 1-cell/HPF Nil 1-cell/HPF 
Crystals Nil Nil Nil Nil 
Casts Nil Nil Nil Nil 
Others Bacteria seen Bacteria seen Bacteria seen Bacteria seen 
Values are mean of 6 animals ± S.E.M. (Dunnett's test). *P<0.05; **P<0.01. vs. control group  
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Table 8. Effect of oral administration of Lingathi Mathirai on organ weight 
Dose (mg/kg) Control 100 mg/kg 200 mg/kg 400 mg/kg 
Heart(g) 0.60±0.06 0.57±0.05 0.56±0.07 0.55±0.06 
Liver(g) 4.5±0.50 4.18±0.34 4.72±0.62 4.66±0.55 
Lung(g) 0.72±0.04 0.65±0.07 0.70±0.05 0.68±0.05 
Spleen(g) 0.61±0.14 0.66±0.04 0.70±0.05 0.68±0.05 
Kidney(g) 1.22±0.3 1.28±0.03 1.27±0.3 1.34±0.04 
Testis(g) 1.00±0.03 0.94±0.05 0.95±0.05 0.94±0.04 
Ovary(g) 0.04±0.02 0.05±0.02 0.04±0.02 0.04±0.02 
Brain 0.77±0.09 0.73±0.06 0.74±0.04 0.75±0.04 
Pancreas 1.45±0.05 1.34±0.08 1.35±0.07 1.34±0.08 
Uterus 0.72±0.05 0.75±0.06 0.74±0.06 0.72±0.04 
Values are mean ± S.E.M. (Dunnet’t' test). nsP > 0.05; Vs Control N=6. 
 
 
124 
 
DRUG OF LINGA MATHIRAI 
HISTOPATHOLOGY 
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EVALUATION OF ANTIHISTAMINIC AND BRONCHODILATOR 
ACTIVITY OF LINGATHI MATHIRAI 
INTRODUCTION 
 Allergy is one of the common diseases that affect mankind with diverse 
manifestations. The prevalence of allergy and asthma has risen in the recent 
years despite an improvement in the general health of the population. Allergic 
diseases are responsible for significant morbidity and have severe economic 
impact. Various epidemiological studies have identified the causes for an 
increase in the prevalence of upper and lower respiratory tract allergic diseases. 
Some of the postulated reasons are increasing environmental pollution and 
increased predisposition of individuals producing excessive IgE through a 
major change in the gene pool, changing lifestyles, and an increasing 
awareness of the disorders. Intensive research during the last several decades 
has highlighted the role of lymphocytes, immunoglobulins, mast cells, and 
various autacoids in the etiopathogenesis of allergic conditions.  
 In the present study, guinea pigs were used because of the extreme 
sensitivity of their airways to the primary mediators of bronchoconstriction, 
including histamine and leukotrienes and their ability to be sensitized to foreign 
proteins. Although there are various model of asthma, guinea pig airways react 
to histamine, acetylcholine, leukotrienes and other bronchoconstrictors in a 
manner similar to that seen in humans. Another similarity between the guinea 
pig model and asthmatic patients is that enhanced bronchoconstriction occurs 
in both species following sensitization, in response to β-adrenergic antagonists. 
Thus, the guinea pig model resembles the human allergic pathology in several 
aspects, especially in terms of mediator release. Histamine antagonists can be 
conveniently recognized and assayed by their ability to protect guinea pigs 
against lethal effects of histamine-induced bronchospasm.   
 As a public health problem, asthma is an important allergic disorder. 
The incidence is on rise all over the world. Globally 18,000 deaths occur per 
year due to asthma. Many anti-asthmatic agents such as mast cell stabilizer, 
leukotriene antagonist, corticosteroids etc are available for the treatment of 
asthma, but these synthetic agents are associated with drawbacks such as high 
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cost, inaccessibility and untoward effects. These factors have contributed to the 
recent increase in the use of traditional based medicinal products. 
 Drug development for asthma has been directed at improving existing 
agents and expanding new modalities that target the Th2 allergic cascade. In 
the hope that Lingathi Mathirai can be a better therapeutic agent for the 
treatment of asthma with less or no side effects we aimed at evaluating the 
potency in asthma management using animal models. 
MATERIALS AND METHODS 
DRUGS AND STOCK SOLUTION  
 Drugs used were Histamine diphosphate (Sigma Chemical, USA) and 
Promethazine hydrochloride (Rhone – Poulenc, Mumbai). Histamine 
dihydrochloride was dissolved in distilled water and desired concentrations 
were prepared. The test drug Lingathi Mathirai concentration was 
100microgram per ml prepared by suspending with 2% CMC and then the 
volume was adjusted to 10 ml with normal saline for making the concentration 
of 100 μg/ml.in distilled water. 
Animals 
 Male albino guinea pig weighing 350– 400g was kept in fasting 
condition 18 hours prior to commencement of experiment and given water ad 
libitum. It was housed under standard laboratory conditions of temperature (25 
± 2°C) and 12/12 hr light/dark cycle and then sacrificed by a blow to the head 
and exsanguinated as per CPCSEA recommended guidelines.( 
In-vitro antihistaminic study 
 Guinea pig was sacrificed and a segment from ileum (2 cm) was 
dissected from the terminal ileum and mounted in an organ bath containing 
Tyrode solution (10 ml) between two stainless steel hooks under 0.5 to 1 g 
initial tension. The lower hook was fixed at the bottom of the organ bath and 
upper one was connected to an isotonic transducer. The Tyrode solution 
composition (pH 7.4) was (concentration in gm/lit.) NaCl 8.0, KCl 0.2, CaCl2 
0.2, MgCl2 0.1, NaHCO3 1.0, NaH2PO4 0.05, and Glucose 1.0gm/liter. It was 
continuously aerated and maintained at 37 ± 0.5ºC The equilibrium period was 
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60 min and the bath solution was refreshed every 15 min. After equilibrium 
period, a dose response curve for histamine in variant molar concentrations, by 
maintaining 45 min time cycle.  
BRONCHODILATOR STUDY 
 Animals were divided into four groups of six animals each. Each animal 
were served as its own control. Animals belonging to each group were 
subjected to a histamine aerosol (0.2% Histamine diphosphate in saline) using a 
glass nebuliser for 2 sec in an airtight Perspex chamber. Aerosolization of the 
solution was achieved via a compressed air line operating at a pressure of 8 Psi 
and a flow rate of 5ml/min. After exposure to the histamine aerosol, the animal 
showed signs of immediate immobilization and bouts of coughing. This was 
followed by shallow breathing symptoms, after which the animal collapsed, fell 
on its back and convulsed. The time taken by the animal to fall on its back after 
exposure to the aerosol was designated as the exposition time. The exposition 
time for each animal in all the four groups was noted.  
 Once the animal fell on its back, it was immediately taken out of the 
chamber and exposed to fresh air where the animal returned back to normal. 
After 1 hour the animals in the first three groups were administered orally 100, 
200 and 400 mg/kg p.o, of Lingathi Mathirai respectively. While the fourth 
group of animals received 300µg/kg of Promethazine by oral route. One hour 
later, the animals were reexposed to the aerosol and exposition time for each 
animal was noted. The difference in the exposition time before and after 
Lingathi Mathirai administration was taken as a measure of the protective 
effect. Percent protection afforded by the Lingathi Mathirai was calculated by 
the formula. 
     Eta-Etb 
       Percentage Protection = --------------x100 
        Etb 
 
 Where ‘Eta’ is the mean exposition time after treatment with extract and 
‘Etb’ is the mean exposition time before treatment with extract. 
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Statistical Analysis 
 Ileum contractions induced by agonist were assumed as 100% and 
reductions induced by test drug calculated. Percentage of ileum contraction was 
expressed as mean ± SEM. Results were analyzed using one-way analysis of 
variance (ANOVA). Probability value less than 0.05 were considered as 
significant 
RESULTS AND DISCUSSION 
 No animals died during the acute toxicity test, nor were any adverse 
effects detected in animals treated with Lingathi mathirai at 2000mg/kg. This 
indicates that the drug is nearly nontoxic in mice up to an oral dose of 2.0 g/kg 
of body weight. One by twentieth, one tenth and one fifth of dose was selected 
from acute toxicity study and administered to animals.   
 Histamine when inhaled has been shown to induce bronchoconstriction 
by direct H1-receptor activation and also by a naturally mediated 
bronchoconstrictor effect via vagal reflexes results in preconvulsive dyspnea 
and it also may lead to the appearance of convulsions. In the present study of 
Lingathi Mathirai have been shown the significant increase in pre-convulsion 
time due to pre-treatment with Lingathi Mathirai at the dose of 100, 200 and 
500mg/kg of body weight of guinea pigs, when the guinea pigs were exposed 
to histamine.  
 The percentage protection of Lingathi Mathirai -100, 200, 500mg/kg is 
27.43, 28.79, 29.83% and standard drug showed 50.31% respectively. The 
guinea pigs exposed to histamine aerosol showed signs of progressive 
dyspnoea leading to convulsions. The results presented here confirm the 
traditional claim that lingathi Mathirai confer some protection on guinea-pigs 
against the effects of a histamine aerosol. The immediate protection is not 
statistically significant but later extended, however the protection is not 
prolonged. Under the conditions employed, Lingathi Mathirai was found to 
possess moderate antihistaminic activity.  
CONCLUSION 
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 The results of present study suggested that Lingathi Mathirai 
significantly protected the Guinea pigs against histamine-induced 
bronchospasm. The traditional use of Lingathi Mathirai is substantiated in the 
management of asthma. The Lingathi Mathirai at moderate dose level 
significantly prolonged the latent period of convulsions as compared to control 
following the exposure of histamine aerosol. The action started after 90minutes 
of drug administration. Thus, our findings suggest that Lingathi Mathirai 
possess significant antihistaminic activity.  
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Table-1: Effect of Lingathi Mathirai on isolated Guinea pig ileum 
preparation  
Values are expressed in mean ± SEM, *p< 0.05 compared with 
histamine induced contraction (45mm as 100%); n=3. 
 
 
 
 
 
 
 
 
 
 
 
Sr. 
No 
Dose of Histamine 
(μg/ml) 
Percent of maximum response 
Histamine alone 
Histamine+Lingathi 
Mathirai (1mg/ml) 
1 1 0.3±0.04 0.10±0.01 
2 2 0.5±0.04 0.2±0.02 
3 4 0.5±0.03 0.3±0.26 
4 10 2.5±0.82 1.1±0.30 
5 20 3.8±0.96 1.9±0.55 
6 40 5.8±1.02 2.5±0.72 
7 80 6.6±1.11 2.7±0.81 
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Table-2: Bronchodilator effect of Lingathi Mathirai on Histamine induced 
Bronchoconstriction. 
Treatment Pre-Treatment 
Exposition in 
seconds 
Post-Treatment 
Exposition in 
seconds 
Percentage 
Protection 
 
Lingathi Mathirai 
100mg/kg. p.o. 
88.02 ±3.65 121.30±3.72**  27.43% 
Lingathi Mathirai 
200mg/kg. p.o. 
91.24±3.00 128.13±4.98** 28.79% 
Lingathi Mathirai 
400mg/kg. p.o. 
95.11±3.45 135.56±5.45** 29.83% 
Promethazine 
(300mg/kg, p.o) 
89.15±3.15 179.44±6.10** 50.31% 
N=6; Values are expressed as mean ± SEM; *Significant between pre and post 
treatment time (Student’s –‘t’) **P<0.01. 
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BIO STATISTICAL ANALYSIS 
 
Treatment for Swasa Kasam 
 
The most popular statistical tool, namely, Fisher’s Exact Test analysis 
has been employed to analyses the effectiveness with the help of a hypothesis. 
 
Hypothesis 
There is no reducing symptoms among the patients for the treatment of 
Swasa Kasam. 
 
 
 
 
Symptoms 
Number of Cases 
Reduced Not Reduced 
Dyspnoea, Wheezing 14 
70% 
6 
30% 
Cough with Expectoration 11 
84.6% 
2 
15.4% 
Sneezing, Rhinitis 5 
71.4% 
2 
28.6% 
 
 
Software: spss17 version 
Number of cases: 40 
Test: Fisher’s Exact test 
Confidence Interval: 95% 
Result: 
P Value (2 tailed): p<0.01 
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Inference:  
Since the p value is significant (<o.o1), The hypothesis is not accepted. 
So there is significant reduced symptoms among the patients for the treatment 
of Swasa kasam. Hence it is concluded that the treatment was effective and 
significant. 
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Consent form 
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CONSENT FORM 
 
 I certify that I have disclosed all the details about the study in the terms 
readily understood by the patient. 
DATE:        SIGNATURE 
         NAME 
 
CONSENT BY THE PATIENT 
 
 I have been informed to my satisfaction by the attending physician the 
purpose of the clinical trial and the nature of the drug treatment and follow up 
including the lab investigations to be performed to monitor and safeguard my 
body functions. 
 
 I am aware of my right to opt out of the trial at any time during the 
course of the trial without having to give reasons for doing so. 
 
 I exercising my free power of choice, hereby give my consent to be 
included as a subject in the clinical trial of LINGA MATHIRAI for the 
treatment of SWASA KASAM. 
DATE:       SIGNATURE 
        NAME
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§¿¡Â¡Ç¢Â¢ý ´ôÒ¾ø ÀÊÅõ 
 
 
           ¾¢Õ. ___________________________¬¸¢Â ¿¡ý 
___________ÅÂÐ,         
(____________________________________________________
_____________________________________________________
___________, Åº¢ìÌõ þ¼õ) ±ý ÍÂ ¿¢¨É×¼ý ±Ø¾¢ì ¦¸¡ÎìÌõ 
´ôÒ¾ø ÀÊÅõ. 
 
          ¿¡ý ÍÅ¡º ¸¡ºõ(þ¨ÃôÒ þÕÁø) ±ýÛõ §¿¡Â¡ø À¡¾¢ì¸ôÀðÎ 
¦ºý¨É,«ÃÍ º¢ò¾ ÁÕòÐÅ ¸øæ¡¢Â¢ø  (þ¼õ: «È¢»÷ «ñ½¡ 
þó¾¢Â ÁÕòÐÅÁ¨É, «ÕõÀ¡ì¸õ, ¦ºý¨É-106.) ¿¼ò¾ôÀÎõ º¢ò¾ 
ÁÕòÐÅ ¬Ã¡öîº¢ ãÄõ º¢¸¢î¨º ¦ÀÈ ±ý ÍÂ ¿¢¨É×¼ý 
ÓØºõÁ¾ò¨¾Ôõ ¦¾¡¢Å¢òÐì¦¸¡û¸¢§Èý. 
 
          þó¾ ¬Ã¡öîº¢Â¢ý §¿¡ì¸õ, ÁÕòÐÅõ ¦ºöÔõ Ó¨È, 
¦¾¡¼÷¸ñ¸¡½¢ôÒ ÁüÚõ ±ý ¯¼ø¿Äõ ÌÈ¢ò¾ ÁÕòÐÅ 
À¡¢§º¡¾¨É¸¨Çô ÀüÈ¢Â Å¢¡¢Å¡É Å¢Çì¸õ ±ÉìÌ ÁÕòÐÅõ ¦ºöÔõ 
ÁÕòÐÅ÷ ãÄõ ¦¾Ç¢×ÀÎò¾ôÀðÎûÇÐ. þó¾ ¬Ã¡öîº¢Â¢ø 
ÀíÌ¦¸¡ûÙõ ±ý ºõÁ¾ò¾¢üÌ Â¡Õ¨¼Â ¿¢÷Àó¾Óõ ¸¡Ã½Á¢ø¨Ä 
±ýÀ¨¾ ¦¾¡¢Å¢òÐì¦¸¡û¸¢§Èý. 
 
 
 
 
þôÀÊìÌ, 
 
 
¦ÀÂ÷     : 
Ó¸Å¡¢  : 
 
¿¡û      : 
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Case sheet proforma 
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CASE SHEET  
POST GRADUATE DEPARTMENT - BRANCH-I 
 (POTHU) MARUTHUVAM  
GOVT. SIDDHA MEDICAL COLLEGE & ANNA HOSPITAL, CHENNAI-106. 
CASE SHEET PROFORMA FOR “SWASAKAASAM” 
WARD NO. : NATIONALITY : 
I.P. NO : RELIGION : 
BED NO : OCCUPATION : 
NAME : INCOME : 
AGE : D.O.A : 
SEX : D.OD                            : 
PERMANENT ADDRESS :  
  DIAGNOSIS : 
 
TEMPORARY ADDRESS:  
Govt. Siddha Medical College & 
Anna Hospital, Chennai – 106.                            MEDICAL OFFICER : 
 
 
 
COMPLAINTS AND DURATION : 
 
 
 
 
 
HISTORY OF PRESENT ILLNESS : 
 
 
 
 
HISTORY OF PAST ILLNESS : 
 
 
 
 
PERSONAL HISTORY & HABITS : 
A. Food    : Veg   Non veg 
B. Marital status    : single    married 
C. Duration of married life : 
FAMILY HISTORY 
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GENERAL EXAMINATION: 
1. Physical build :      lean                    normal                   obese  
2. Height (cm) : 
3. Weight(kg)  : : 
4. Pulse rate  : 
5. Heart rate : 
6. Respiratory rate : 
7. Blood pressure  : 
8.  Pallor   : 
9. Cyanosis  : 
10. Jaundice : 
11. Clubbing  : 
12. Pedal oedema : 
13. JVP  
EXAMINATION OF VITAL ORGANS 
• CVS   : 
  
• CNS  :  
 
• Respiratory system     : 
  
• Digestive system : 
  
• Urogenital  system :  
SIDDHA ASPECTS 
Yaakai (udal nilai)      Mukkunam  
1. Vatham        1. 
Sathuva gunam 
2. Pitham       2. 
Raasatha gunam  
3. Kapham       3. 
Thamo gunam 
4. Kalappu 
 
PARUVA KAALAM (SEASONS)  NILAM (PLACES) 
1. Kaar Kaalam (Aavani-Puratasi) Aug-sept.   1.Kurinchi (Hills  Areas) 
2. Koothir Kaalam (Iypasi-Karthigai) Oct-Nov. 2.Mullai (Forest Areas) 
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3. Munpani  Kaalam (Maargazhi-Thai) Dec-Jan. 3.Marudham (Fertile 
Areas) 
4. Elavenil Kaalam (Chithirai-Vaikasi) Apr-May 4.Neithal (Sea Areas) 
5. Mudhuvenil  Kaalam (Aani-Aadi) Jun-Jul 5.Paalai (Desert Areas) 
 
IYAMPORIGAL/PULANGAL  KANMENTHIRIYAM / 
KANMAVIDAYAM 
1. Mei  (Sensation)  1.Kai [Koduthal] 
2. Vaai (Taste)  2.Kaal [Nadathal] 
3. Kann  (Vision)  3.Vaai [Pesal] 
4. Mooku(Smell)  4.Eruvai [Malam Kazhithal] 
5. Sevi (Hearing) 5.Karuvai [Aananthithal] 
 
MUMMALAM 
1. Malam 
2. Moothiram 
3. Viyaravai 
 
UYIR THATHUKKAL: 
 Vatham: 
1. Pranan   6.  Naagan 
2. Abanan   7.  Koorman 
3. Viyanan   8.  Kirukaran 
4. Udhanan   9.  Devadathan 
5. Samanan  10. Dhananjeyan 
 
PITHAM:   KAPHAM: 
1. Anal Pitham  1.  Avalambagam 
2. Ranjaga Pitham   2.  Kledagam 
3. Saadhaga Pitham   3.  Podhagam 
4. Aalosaga Pitham   4.  Tharpagam 
1. Prasaga Pitham  5.  Santhigam 
 
UDAL THATHUKKAL: 
1. Saaram 
2. Senneer 
3. Oon 
4. Kozhuppu 
5. Enbu 
6. Moolai 
7. Sukkilam / Suronitham 
 
Envagai Thervu: 
1. Naa -  
2. Niram 
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3. Mozhi -  
4. Vizhi -  
5. Sparisam 
6. Malam  
a. Niram 
b. Nurai 
c. Erugal   
d. Elagal 
7. Moothiram 
a.  Neerkuri  
1.  Niram 
2. Edai 
3. Manam 
4. Nurai 
5.  Enjal 
b. Neikuri 
8. Naadi  
 
 
 
 
 
SIGNS AND SYMPTOMS 
 
               PRESENT                   ABSENT 
1. Dyspnea 
2. Cough & expectoration 
3. Tightness of chest 
4. Rhinitis 
5. Sneezing 
6. Fever 
7. Headache 
8. Cyanosis 
9. Clubbing 
10. Loss of weight 
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Assessment Before 
Treatment 
After Treatment 
I II III IV 
1. Dyspnea      
2. Cough & 
expectoration 
     
3. Tightness of 
chest 
     
4. Rhinitis 
5. Sneezing 
     
6. Fever      
7. Headache      
8. Cyanosis      
9. Clubbing      
10. Loss of weight      
 
LABORTORY INVESTIGATIONS: 
 
                              BT                                 AT 
 
1.Blood  Tc 
   Dc 
   ESR 
   Hb 
   Bl-sugar (R) 
   Bl.Urea 
   Sr.Cholesterol 
   Sr.Creatinine 
         Sputum for AFB 
                   Mantoux test 
 
2.Urine - alb 
   Sug 
   Dep 
 
3.X-ray Chest PA View 
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DRUG: :  LINGATHI MAATHIRAI:                                                                                                                                            
Dose: :      130mg, tid.  
Anubanam: water   
Duration of treatment: 48 days.                 
 
Pathiam (Do’s and Don’ts) 
 
 
 
Prognosis at the end of the treatment 
 
 
 
 
 
 
 
 
Medical Officer Signature:      H.O.D
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